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MarketThe rectal route can be considered a good alternative to the oral route for the paediatric population because these
dosage forms are neither to be swallowed nor need to be taste-masked. Rectal forms can also be administered in
an emergency to unconscious or vomiting children. Their manufacturing cost is low with excipients generally
regarded as safe. Some new formulation strategies, including mucoadhesive gels and suppositories, were intro-
duced to increase patient acceptability. Even if recent paediatric clinical studies have demonstrated the equiva-
lence of the rectal route with others, in order to enable the use of this promising route for the treatment of
children in the 21st Century, some effort should be focused on informing and educating parents and care givers.
This review is the ﬁrst ever to address all the aforementioned items, and to list all drugs used in paediatric rectal
forms in literature and marketed products in developed countries.
© 2014 Elsevier B.V. All rights reserved.Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2. The child and human dimensions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.1. The child dimension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.2. The human dimensions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.2.1. General considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.2.2. Drug factor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.2.3. Dosage form factor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.2.4. Administration devices and ease of administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.2.5. Patient barriers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
3. Paediatric rectal dosage forms on the market and in the scientiﬁc literature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.1. Rectal dosage forms in Pharmacopoeias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.2. Paediatric rectal dosage forms on the market . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.2.1. USA, Japan and 5 European countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.2.2. Case study in France: evolution of the market over the last 20 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
3.3. Paediatric rectal forms cited in the scientiﬁc literature: a scoping exercise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
3.4. Suppositories: considerations for paediatric dosing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.4.1. Choice of the excipient . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.4.2. Manufacturability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.4.3. Pharmacotechnical testing of suppositories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
4. Paediatric clinical studies: a 10-year overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
4.1. Analgesics, antipyretics and NSAIDs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
4.2. Antiepileptics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
4.3. Antimalarial drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
5. The future . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
5.1. In vitro and preclinical studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
5.1.1. Thermosensitive and/or mucoadhesive gels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44ews theme issue on "Drug delivery and the paediatric population: where are we at?".
Saint-Priest cedex, France. Tel.:+33 4 72 22 98 38; fax: +33 4 78 90 45 67.
35V. Jannin et al. / Advanced Drug Delivery Reviews 73 (2014) 34–495.1.2. Suppositories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
5.1.3. Other forms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
5.2. Vaccination by the rectal route . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
6. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 451. Introduction
Rectal forms are one of the oldest pharmaceutical dosage forms as
their origin goes back to antiquity. The Old Testament refers to
‘Magerarta’ – suppository made of silver – and Hippocrates describes
various compositions of acorns which were rectal dosage forms for
local effects. The ﬁrst usage of the word suppository goes back to 1763
in the Universal Pharmacopoeia of Lemery. The term suppositorium
comes from the Latin word supponerewhich means ‘substitute’ because
this dosage form was introduced as a substitute to enema [1].
At ﬁrst rectal dosage forms were composed of solid supports im-
pregnated with medicinal substances. These supports were made of
baked honey, soap, tallow or even horn. These solid supports were
substituted by cocoa butter in the late 18th Century. The ﬁrst mention
of the addition of an active substance in the suppository mass was
made by Henry and Guibourt in 1841 by the introduction of opium pel-
lets in the molten cocoa butter before moulding [2]. At that time the
classical weight of a suppository for adults was 5 g. In the following cen-
tury two alternative masses were proposed to cocoa butter: ﬁrstly a
mixture of gelatine, glycerine and water in 1897, and secondly, hard
fat which was introduced after the Second World War due to shortage
of cocoa butter. In the 20th Century, most of the rectal drug products
on the market were suppositories composed of fatty bases (hard fat),
and are nowadays around 2 g for adults and 1 g for children. These rectal
forms were particularly used in some European countries and in Japan
where the use of suppositories ismore accepted than in other territories
like the United States of America or Laos for example. The ﬁrst literature
reference on the use of paediatric rectal dosage form (for premedication
before anaesthesia) was reported in 1936 [3]. Even, if suppository was
quite popular for adults during the 20th Century, theﬁrstmarket autho-
risation for a Paracetamol paediatric suppository in France was only
granted in 1981 (Doliprane, Sanoﬁ).
Administration of drug through the rectal route is amenable to both
local and systemic drug delivery. It has been effectively used during the
last centuries to treat local diseases of the anorectal area (for example
haemorrhoids) as well as to deliver drugs systemically as an alternative
to the oral route (including antipyretic and analgesic drugs such as Para-
cetamol or Diclofenac) [4]. The latter case can be useful for drugswhich:
- possess limited absorption in the upper gastrointestinal tract,
- are unstable to proteolytic enzymes,
- exhibit a high hepatic ﬁrst pass effect,
- cause irritation to the gastric mucosa,
- or need high doses and cannot easily be formulated in oral solid
dosage forms.
The lower rectum is drained by the lower andmiddle haemorrhoidal
veins and bypasses the liver, hence avoiding at least partially, the hepat-
ic ﬁrst pass effect and allowing drugs to exert systemic effect prior to
metabolism in the liver. The rectal region is also extensively drained
by the lymphatic circulation and could increase the systemic absorption
of some highly lipophilic drugs. In adults, rectal dosage forms should be
inserted in the lower part of the rectum to avoid the absorption of the
drug by the upper haemorrhoidal vein which supplies blood to the por-
tal vein. In addition, the empty rectumpresents a constant and static en-
vironment as compared to the upper gastrointestinal tract, where the
environment varies greatly depending on the section (e.g. pH, volume
of stomach vs. duodenum) and in fasted or fed conditions. The volumeof liquid is reported as relatively low (1–3 mL) and the pH neutral
(pH 7–8) with low buffer capacity [4]. Its surface area is reported to be
of about 200–400 cm2, without villi and microvilli, which is smaller
than the upper gastrointestinal tract, but larger than nasal and buccal
absorptive surfaces. However the epithelia in the rectum is made by a
single layer of columnar or cuboidal cells and goblet cells, histologically
similar to the upper gastrointestinal tract, giving them comparable
abilities to absorb drugs [5].
Rectal dosage forms are also a good alternative to the peroral route
for certain groups of patients who cannot easily swallow tablets or
capsules: this can be in the case of children and the elderly, as well as
in the cases where patients may be unconscious or vomiting.
Despite being one of the enteral routes, rectal drug delivery is not as
popular as the oral route for various obvious and less obvious reasons.
The aim of this review is to investigate these by looking at its applicabil-
ity in children, its applicability to treat various conditions (whether
already implemented in practice or under research) and also the appli-
cability of various traditional or more novel dosage forms, to assess if
and when it could have the desirable attributes for paediatric drug
delivery.
2. The child and human dimensions
2.1. The child dimension
Designing any formulation implies that patient factors are taken into
consideration. For paediatric subsets, extra challenges occur, the very cen-
tral one being that children undergo physiological changes that could af-
fect the pharmacokinetic/pharmacodynamic/pharmacogenomics. This is
why the International Conference on Harmonisation [6] has proposed a
subdivision for the purpose of paediatric medicines development to
reﬂect biological ages.
− Preterm newborn infants
− Term newborn infants (0 to 27 days)
− Infants and toddlers (28 days to 23 months)
− Children (2 to 11 years)
− Adolescents (12 to 16/18 years, dependent on region).
The guideline on the investigation of medicinal products in the term
and preterm neonate [7] states that rectal administration is not com-
monly used in these subsets and that it is associatedwith erratic absorp-
tion. If considered, it must be fully evaluated for safety and efﬁcacy, in
addition to appropriate bioavailability studies. Moreover rectal dosage
forms should be used with extreme caution in premature infants, as
the delicate rectal lining could be torn, introducing infection. For similar
reasons it is not recommended to use this route in immunocompro-
mised patients to avoid the risk of trauma leading to possible abscess
formation [8].
However, more generally for the rectal route, similarities and differ-
ences between adults and children of various ages have not been
systematically reported, despite this route being considered from pre-
ferred acceptability to best/preferred applicability in children under
6 years of age (preschool) [9].
Like most of the gut, the rectum is formed at birth but is only func-
tional when the baby starts to feed orally, when development continues
andwhen commensal bacteria and immunity kick in. Themain anatom-
ical difference is in size as described in Table 1 [10]. Therefore, if the PK
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properties, the possible changes of surface area for absorption add to
the reported inconsistency of this route. If in turn the dominant factor
is the ﬁrst-pass metabolism, then as with adults, it depends on where
the drug will be absorbed for children too. It is said that when inserting
suppositories into children, the position beyond the rectal opening
should be adapted to the size/age of the child. Some pragmatic ap-
proaches to determine the appropriate position have been proposed
e.g. using size of knuckles of ﬁngers, more than any evidenced approach.
Of the presystemic paediatric patient factors to consider, the contact
time of the drug to be absorbed is paramount, as its retention will di-
rectly dictate its bioavailability and predictability of the clinical effect.
It is therefore important to explore rectal motility and rectal activity
patterns, keeping in mind that unlike the small intestine, no cyclic
motor activity takes place.
The rectum is the last, usually empty, portion of the large intestine
located above the anal canal, where stools collect prior to evacuation
from the body. The earliest stool of a new born is called meconium,
which should be passed promptly and completely within about 2 days
of birth. It is composed of materials ingested in utero such as intestinal
epithelial cells, lanugo, mucus, amniotic ﬂuid, bile, and water. It is
odourless, almost sterile, viscous and sticky. From a dark greenmeconi-
um, stools progress toward yellow (digested milk), until the introduc-
tion of weaning semi-solid foods at or around 6 months, when it
changes to brown.
Faecal continence is maintained by the coordinated function of the
pelvicﬂoor, rectumand anal sphincters.When fullness (rectal distension)
is felt, the abdominal muscles contract, increasing intra-abdominal
pressure. The puborectal sling and the sphincters relax, and the rectal
musculature contracts. The colon and rectum then descend, the rectum
becomes elongated, faeces are discharged, and the anal canal is closed
by its sphincters.
The normal frequency of evacuations has an inverse relationship
with age. In breastfed infants, it was shown that the average daily defe-
cation frequency halved during the ﬁrst 3 months, whereas no signiﬁ-
cant changes were observed in infants fed standard formula or mixed
feeding [11]. By 16 weeks, 2 was the mean frequency of bowel actions
per day of infants of both feeding groups [12]. From the age of 3 years,
normal stool frequency varies from three stools per week to three per
day. Between 5 years and 8 years of age, the majority of children have
a medium-sized bowel movement daily or every other day without
straining or withholding [13]. In turn the passage of three or more
loose or liquid stools per day is considered to be diarrhoea (WHO). Re-
gardless of age, this high variability in what is perceived to be normal
impacts on the applicability of the rectal route.
Moreover, applicability relies aswell on the ability of the patient,who
might need to hold the medicine to counteract the possible urge to pushTable 1
Age related changes in rectal dimensions adapted from [9] (A) and calculated volume of 1 g an
A
Age Diameter (cm) Length (cm)
1 month 1.5 3
3 months 3.0 6
1 year 3.5 7
2 year 4.0 8
6 year 4.5 9
10 year 5.0 12
B
Density (g/cm3) Volu
Water 1.00 1.00
Cocoa butter 0.86 1.16
PEG 400 1.13 0.89
Glycerinated gelatine 1.20 0.83it out. Voluntary control of the external anal sphincter is key in the volun-
tary deferring of evacuation until a socially opportune moment. Recent
studies show most children to start bowel training between 24 and
36 months of age and fewer articles report it from 12 month onwards
[14]. Ability to control sphincters requires coordination by the patient.
It changes with development and depends not only on behaviour/
training but also on integration of involuntary and voluntary neurolog-
ical and muscular mechanisms, as well as cognitive control.
Constipation in children is a common health problem with a world-
wide prevalence between 0.7% and 29.6% from newborns to young
adults [13] and many children suffer from haemorrhoids too. Also, it
has been estimated that children under 5 years have a global average
of three bouts of diarrhoea per year compared to just under one in
adults [15]. This higher incidence of gastrointestinal disorders is
obviously not favourable for optimal rectal drug delivery.
Regardless of the extent of bacterial survival, there seem to be
some residual bacterial enzymes in the rectum [16]. Nevertheless it is
generally considered that presystemic loss by adsorption to faeces,
intraluminal degradation by microorganisms, metabolism within the
mucosal cell, and lymphatic drainage do not signiﬁcantly affect the
fate of rectally administered drugs [17]. However, there is a general
lack of recent research work around rectal biopharmaceutical proper-
ties even in adults. In turn, the degree of ionization of a drug of a certain
pKa depends on the rectal pH which is neutral (7.9) in adults [18].
The mean rectal contact pH was reported to be 9.6 with a wide range
(7.2–12.1) for 100 healthy children aged less than 14 years (excluding
neonates) [19]. This was not conﬁrmed in a recent paper where pHmea-
sured in infants were just below neutrality [20]. Moreover there was no
signiﬁcant difference between well and unwell infants: 6.69 (95% CI
6.55–6.83) vs. 6.88 (95% CI 6.64–7.12) respectively, with rectal pH
signiﬁcantly lower in neonates 6.47 (6.29–6.65), yet still around the
neutral region [20]. The only difference between the two papers being
that the earlier measurements were only done if the rectal ampulla was
free of faeces. Digital examination was not always done in the recent
paper.
To conclude, there is very little speciﬁc information on paediatric
rectal biopharmaceutical properties in the literature, let alone on per-
meability itself. It might be explained by the lack of popularity of this
route as explained in the next sections, leading to a lack of research
interests.
2.2. The human dimensions
2.2.1. General considerations
The breadth of potential for use of the rectal route in community and
hospital settingswill be clearly highlighted in the next section of this re-
view. But does it make it appropriate for paediatrics?d 2 g suppositories (B).
Surface area (2 π r 2 + 2 π r h) (cm2) Volume (2π r2 h) (cm3)
18 11
71 85
96 135
126 201
159 286
228 471
me of 1 g suppository (cm3) Volume of 2 g suppository (cm3)
2.00
2.33
1.77
1.67
Fig. 1. Example of dividable stick-shaped suppositories (scale in cm).
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the case of suppositories, dose adaptation can be a problem. However
some new technologies such as dividable stick-shaped suppositories
might allow some level of dose ﬂexibility.
The rectal route might not be acceptable for very frequent dosing
(more than once day and/or long term use). At the same time,
prolonged release (if no early expulsion occurs) could be achieved
through formulation, to minimize dosing frequency. It is commonly
used when patients are nauseous or vomiting or in infants/children re-
luctant or unable to take oralmedication if they are very poor, for exam-
ple in fever. The rectal route seems to be valued for out-of-hospital
emergency and life-saving situations. In the United States, Diazepam is
the only FDA approved rectal formulation for the ambulatory treatment
of early status epilepticus. It has even been suggested for its pre-referral
emergency treatment applicability, for example, for malaria or neonatal
sepsis in resource-poor settings. Thismight be due to the relative ease of
administration in these situations and the quick onset of action.
Many articles showed that it can be appropriate for developing
countries. Moreover there is a relatively good production vs. cost bal-
ance as technologies are relatively simple and costs of ingredients are
cheap.
In general, excipients have a good safety proﬁle in children. Some
may be irritant, but as they are quite well established, the risk–beneﬁt
balance can be addressed early in development. In terms of risk of sys-
temic toxicity, there is a general paucity of information, especially
when it comes to rectal absorption. However if an excipient has a well
known oral safety proﬁle in the paediatric population, its proﬁle, includ-
ing potential allergies and sensitization, should be similar rectally, as the
rectal epithelium has comparable abilities to absorb drugs. Some con-
cerns are inherently taken out, such as with colouring or taste masking
agents. Indeed, there are no issueswith organoleptic characteristics, but
in turn, different acceptability issues with children and parents/carers
are reported in chronic use, and are not outweighed by practicalities
such as being safely (self) administrable at home.
This administration route is not always reliable as it could suffer
from variable absorption and patient acceptance (age, geo-socio-
cultural background) can also be inconsistent as discussed later.
The reasons for and against developing/using the rectal route in chil-
dren are multifactorial.
2.2.2. Drug factor
There is a multiple risk of presystemic loss mainly from non-
emptiness of the rectum at the time of administration, or/and uncon-
trolled bowel movement upon administration. Combined with variable
location for absorption at administration and considering the anatomy
of haemorrhoidal veins in children is not different than in adults, bio-
availability could be affected. Therefore it seems that the therapeutic
index of the drug and the required speed of absorption will be impor-
tant determinants to choose whether to formulate it for the rectal
route, providing that solubility, stability and permeability are not limit-
ing factors.
2.2.3. Dosage form factor
In the ﬁrst half of the 20th Century the classical weight of supposito-
ries was less than 4 g in Mexico, Italy, Sweden, Germany, and USA; but
up to 8 g in the UK. This may help to explain the lack of development of
this form in this territory. The smallest suppositoryweighted between 1
and 2 g andwasmost probably for paediatric dosing. Nowadays,most of
suppositories weight 2 g for adults and 1 g for infants and children. Only
few paediatric suppositories weight more than 1 g: laxative supposito-
ries of glycerine weight up to 4 g and some drugs requiring high dosage
(Metronidazole or Mesalazine for example) weight 2 g. Liquids, espe-
cially with larger volumes, would require the child to be able to hold
in the medicine which is impossible in neonates and infants. Smaller
volumes (1–5mL) havemore favourable acceptability [21]. By adjusting
the viscosity it might be possible to keep the good spreading of liquidsbut facilitate patient retention. For example a Morphine gel was the
preparation of choice compared to solution for 1–10 year old children
in Sweden [22]. However any rectal dosage forms require a dedicated
personal space and some time for administration which might not al-
ways be convenient, on top of being distressful if not painful for some.
The dosage form itself might be irritable to the rectal mucosa be-
cause of its composition (excipients), pH, and osmolarity. It is a well
established way to treat constipation to use osmotic laxatives such as
lactulose and macrogols. Avoiding cold administration (e.g. supposito-
ries kept in the fridge) might increase administration comfort and de-
crease risk of expulsion and interruption of absorption.
2.2.4. Administration devices and ease of administration
It is more common for liquids and semi-solid to be package in or at-
tached to the administration device itself. An applicator can also be dis-
pensed separately. The applicator is usually like a syringe with a
plunger, with or without the possibility to adapt the dose with a rectal
tip of 4.4 to 6 cm. DIASTATAcuDial is a non-sterile Diazepamgel provid-
ed in a preﬁlled unit-dose rectal delivery system for which the dose can
be adjusted. For semi-solid formulations, a tip can be directly screwed
on the tube and cleaned between administrations (Fig. 2).
For suppositories, although simple hygiene before and after adminis-
tration should be sufﬁcient, a ﬁnger cot can also be used. Interestingly,
although it seems much more common for administration of pessaries
or tablets via the vaginal route, very few suppository administration de-
vices seem to be available (Fig. 3) and they are not paediatric speciﬁc
whereas it is generally considered that using an appropriate device is
generally correlated with more compliant administration of drugs [23].
In the case of rectal drug delivery, it might also help to overcome phys-
ical or psychological difﬁculties of administration and help to ensuring
easier and more reproducible administration, which could in turn
switch psychosocial factors such as beliefs, motivation, and attitude.
The suppository inserter shown in Fig. 3 has a 5.1 cm long, hollow
plastic tip that holds a standard suppository, and spring-loaded design
which pushes it out. With the handle, it measures 22 cm long, and can
be sanitized easily. It is constructed from stainless steel with polyethyl-
ene collars and tips. The D-rings on the quad handles allow for easy ad-
justments [24]. The length of rectal tips aforementioned does not seem
adapted to the rectal dimensions of neonates (Table 1) and the usability
in infants and children remains to be established. Lubrication with
water based lubricants, or even water itself, is often recommended to
insert suppositories as well as tips and devices.
2.2.5. Patient barriers
Finally it is important to consider patients' real barriers versus cul-
tural, perceived barriers or lack of understanding of the potential of
Fig. 2. Example of rectal devices: a) enema bottle (all in one); b) DIASTAT AcuDial rectal delivery system. c) Rectal Tube Tip for tubes (4.4 to 6 cm long).
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route might be beside positive pharmacological outcomes aforemen-
tioned, but superseded by ‘age, attitudes and tradition’ [25]. Some studies
were conducted in order to evaluate the compliance and acceptability of
rectal dosage forms. It is inﬂuenced bymany factors: the state of health
of the children, information – or the lack of – provided by the health au-
thority, knowledge of federal advices by the care takers, care givers and
parents, the inﬂuence of healers, the cost of goods, and cultural barriers
[26–32].
It is common knowledge that there are very strong feelings about
the rectal route of administration, especially in United Kingdom [9]. It
is not the aim of this review to ﬁnd out why but to provide some evi-
dence of use and of acceptability, even if sparse and not systematic. A
study in UK in the nineties examined the preference for routes of
administration of post-operative analgesia. Adult patients were more
tolerant of suppositories than hospital staff; however the majority pre-
ferred the intravenous route [33]. In another UK study parents rated the
rectal route themost unpleasant compared to oral andparenteral routes
[34]. However this is not necessarily always the case: in a study in Niger,
the dropout rate after 3 days was higher in the intramuscular group as
compared to patients treated with intrarectal quinine cream [35].
One can wonder whether in certain countries/regions the rectal
route is not used because dosage forms available are not prescribed/ac-
cepted, because there are none available due to alternative choices, or if
this is driven by social attitudes andmarket response This is highlighted
in emergency situations such as seizure management where the rectal
route is used because outside of psychosocial negative factors, it has
been shown to be effective, safe, and simple to use versus intravenous
or even nasal administration [36,37]. It has also been praised to decrease
themortality of severe malaria due to treatment delays and to decrease
the side-effects due to intramuscular administrations in Africa [30,35].
In their position paper on thepharmaceutical development of paediatric
medicines [21], the WHO states that in severe disease conditions, forFig. 3. Example of a) simple applicator sold for ovules pessaries and rectal suppositories (Med
handle 22 cm long [176].example neonatal sepsis, some alternatives such as rectal preparations
may be easier to apply by untrained caregivers. However in similar sit-
uations in other resource-poor settings in theworld, e.g. Laos, use of the
rectal route is mainly hindered by the lack of information and training,
not only to the population but also to the health care teams [38]. On re-
ﬂection, this might also be the case in developed countries, if rectal drug
delivery for young children is favoured in some countries and not even
thinkable in others. Interestingly even if paediatricians' attitudes greatly
inﬂuence parents' behaviours and beliefs, amajority of Italian parents of
children under 6 years reportedly preferred antipyretics suppositories
to oral administration, versus only 27% of paediatricians. Parents sur-
veyed thought that they are more practical, easier, more effective or
faster acting than oral formulation [39]. The relatively good acceptabil-
ity of the rectal route for preschool children versus the oral route was
also reported in studies in Canada [40], and in German, French and Ital-
ian speaking regions of Switzerland [41], aswell as in Iran [42]. However
in another Iranian study parafﬁn oil received higher percentage of fam-
ily satisfaction and compliance orally than rectally [43].
On top of therapeutic need and inﬂuence, age seems to be important
and it is assumed that acceptability among children is generally poor.
However no formal or systematic study or review is available from
their perspective, although other some stakeholders (parents, carers,
prescribers) have been surveyed. In Switzerland paediatricians would
prescribed antipyretic drugs via the rectal routes for children aged
18 months–5 year old, whereas from 6 year old they tended to largely
prescribed oral drugs [44]. It is anticipated that it would not be the
route of choice in teenagers. In fact older children and adults often re-
fuse treatment with Diazepam rectal gel due to social objections [37].
In general, in each society there are socio-cultural norms and recom-
mendations regarding the knowledge, attitude, preference, and behav-
iour of people. It seems that there are many taboos, mainly acquired/
transmitted rather than innate though, that surroundproctology related
topics that could play a role in the reticence of using this route. There is aintin) b) suppository inserter (North Coast Medical, Inc.) Rectal tip 5.1 cm long, with the
Table 2
Rectal forms and sub-categories described in the European Pharmacopoeia 7th edition.
Rectal form Sub-category (if applicable)
Suppositories Hard fat
Macrogols
Cocoa butter
Gelatinous mixtures
Rectal capsules Soft gelatine capsule with a
lubricating coating
Rectal solutions, emulsions, suspensions
Powders and tablets for rectal solutions
and suspensions
Semi-solid rectal preparations Ointments
Creams
Gels
Rectal foams
Rectal tampons
39V. Jannin et al. / Advanced Drug Delivery Reviews 73 (2014) 34–49need for prospective compliance studies to better understand and try to
set up appropriate interventions to alleviate issues with the use of the
rectal route.3. Paediatric rectal dosage forms on the market and in the
scientiﬁc literature
3.1. Rectal dosage forms in Pharmacopoeias
After consultation of the European, US and JapanesePharmacopoeias
(EP, USP, and JP, respectively), only the EP contains a special chapter on
rectal dosage forms entitled “Rectal preparations/Rectalia” [45]. It de-
ﬁnes rectal preparations as ‘systems intended for the rectal use in
order to obtain a systemic or a local effect’. They can also be intended
for diagnosis purposes. Sevendifferent categories of rectal forms are dis-
tinguished as presented in Table 2.
The USP and JP do not include a speciﬁc chapter on rectal forms, but
deﬁne the suppository dosage form. The USP deﬁnes suppositories as
dosage forms adapted for application into the rectum. These supposito-
ries can be composed of cocoa butter, glycerinated gelatine, hydroge-
nated vegetable oils and hard fats, mixtures of polyethylene glycols,
and fatty acid esters of polyethylene glycols. In addition, some other
forms intended for systemic action (called transmucosal route in the
USP) are described, such as: gels, foams, creams, pastes and ointments.
Furthermore, theUSP glossary contains a deﬁnition of the rectal route as
a ‘route of administration (mucosal) characterized by deposition into
the rectum to provide local or systemic effect’. The JP gives a slightly dif-
ferent deﬁnition where suppositories are solid preparations intendedTable 3
Paediatric rectal forms marketed in the USA.
Form Drug Dose Indicationsa; ag
Suppository Bisacodyl 10 mg Laxative (OTC)
Suppository Prochlorperazine 12.5, 25, 50 mg Anti-emetic, an
Suppository Promethazine HCl 12.5, 25, 50 mg Antihistaminic
Suppository Paracetamol 80, 120, 325 mg Pain/antipyreti
Solution Lactulose 10 g/15 mL Laxative; child
Powder Sodium polystyrene sulfonate 454 mg/BOT Hyperkalemia;
Enema Mesalamine 4 g/60 mL Distal ulcerativ
established/pre
Suspension Sodium polystyrene sulfonate 15 g/60 mL Hyperkalemia;
Enema Hydrocortisone 100 mg/60 mL Ulcerative colit
Aerosol Hydrocortisone acetate 10% Ulcerative colit
Gel Diazepam 2.5 mg/0.5 mL Anticonvulsant
Suppository Mesalamine 1 g Ulcerative colit
Suppository Prochlorperazine 25 mg Antiemetic/ant
Suppository Caffeine, Ergotamine tartrate 100, 2 mg Headaches; saf
a All listed drug products are human prescription drug label except those containing ‘OTC’ o
March, 8th 2013).for insertion into the rectal or vaginal cavity. There is nomention of sys-
temic effect in the JP.
3.2. Paediatric rectal dosage forms on the market
3.2.1. USA, Japan and 5 European countries
This overview of the market for paediatric rectal forms was limited
to USA, Japan and Europe.
TheDailyMed [46] and FDA [47]websiteswere consulted to build an
exhaustive list of US paediatric rectal dosage forms presented in Table 3
in order of decreasing number ofmarketed drug products retrieved. The
USmarket comprises a rather large list of rectal dosage forms for paedi-
atric dosing compared to the limited amount of ofﬁcial monographs in
the USP. The main rectal dosage form is the suppository (the only one
with a speciﬁc monograph), but some alternatives exist in the form of
enemas, aerosols, powders, gels or suspensions which can be used for
transmucosal route.
Similarly, the Kusuri-no-shiori drug information website [48] was
used to list Japanese paediatric rectal dosage forms presented in
Table 4, where suppositories seem to be the only rectal dosage form
available for the 4 drugs reported. However, there is no mention of
the children's age in the label/marketing authorisation. Paediatric dos-
ing is adapted by body weight of children, as indicated in the product
label.
The analysis of the European market for paediatric rectal dosage
forms was conducted for ﬁve countries which readily offer access to
their drug product databases: France [49,50], Germany [51], Portugal
[52], Spain [53], and the United Kingdom [54]. European countries
such as France (18) or Germany (23) possess more drugs available as
paediatric rectal dosage forms than the USA (10) or Japan (4). Among
allmarketed drug products availablewithin theseﬁve countries, a series
of six active ingredients were selected for their common use in at least
two countries and reported in Table 5. Like in the USA and Japan, the
main rectal dosage form is the suppository.
Suppositories are prevalent. The main drug available is Paracetamol,
with awide range of doses to accommodate for the age and bodyweight
of infants and children. Diazepammarketed as an adhesive gel supplied
with an applicator is an example of novel rectal dosage form.
The main indications of rectal dosage forms for children in these
three regions are analgesic and antipyretic, anti-inﬂammatory, anti-
emetic and laxative.
It should be noted that the US market is the only region without a
Sodium Diclofenac suppository reference. In turn, in emerging and de-
veloping countries, other rectal paediatric forms are marketed because
of their efﬁcacy, ease of administration and low cost. Hence, supposito-
ries of Artemether and Artemisinin were marketed recently to treate Number of marketed
drug products
; children under 6 years of age: consult a doctor 13
tipsychotic, tranquilizer; from 2 years 10
; From 2 years 9
c (OTC); children under 3 years of age: consult a doctor 9
ren/portal-systemic encephalopathy; from infant 7
from newborn 5
e colitis, proctosigmoiditis or proctitis; paediatric: not still
scription
4
from newborn 4
is; paediatric: not still established/prescription 3
is; paediatric: not still established/prescription 1
; from 2 years 1
is; paediatric: not still established/prescription 1
ipsychotic/tranquilizer; From 2 years 1
ety and effectiveness have not been conﬁrmed/prescription 1
ver-the-counter drug products (14 references selected after a FDA and Daily Med search,
Table 4
Paediatric rectal forms marketed in Japan.
Form Drug Dose Indications, age Number of marketed
drug products
Suppository Paracetamol 50, 100, 200 mg Pain/antipyretic, 10–15 mg/kg (no indication of age, dosing by weight) 2
Suppository Sodium Diclofenac 12.5, 25, 50 mg NSAID, from 1 year (dosing by weight) 1
Suppository Domperidone 10, 30, 60 mg Anti-emetic, under 3 years (dosing by weight) 1
Suppository Sodium bicarbonate, Anhydrous
monobasic sodium phosphate
NA Laxative, no indication of age or weight 1
5 references selected after a Kusuri-no-shiori search, March, 8th 2013.
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rural areas where oral or parenteral dosing is impossible, and hence
substantially reduce the risk of death or permanent disability [55].
Surprisingly, Japan, which was known in the 20th Century for its
commonusage of rectal forms, only possesses a suppositorymonograph
in its Japanese Pharmacopoeia and only four drug products on the pae-
diatric market. It was not possible in the remit of this review to access
sales/market share and prescription trends to link it with the number
of rectal dosage forms aforementioned, except in France.
3.2.2. Case study in France: evolution of the market over the last 20 years
France is one of the main countries for suppository manufacturing
and usage for children. In 1970, 7.5% of all prescriptions in France
were formulations intended for rectal administration (for both adults
and children) [4]. In 2012, rectal forms still represented 1.2% of the
total amount of drug products sold in France (ANSM data, http://
ansm.sante.fr/). This market was studied in depth as paediatric usage
of rectal dosage forms is well documented [56,57]. The evolution of rec-
tal dosage forms in France between 1990 and 2012 is shown in Table 6,
in order to check if the implementation of the European Paediatric Reg-
ulation in January 2007 (Regulation (EC) No 1901/2006 and No 1902/
2006) may have impacted on the availability of rectal dosage forms.
Most of the marketed drug product stayed the same (n = 15), there
were very few introductions of new references (n= 3) but some with-
drawals (n=10). However, among theﬁfteen drug products remainingTable 5
Paediatric rectal forms marketed in ﬁve European countries: France (F), Germany (D), Portuga
Form Drug Country
Suppository Paracetamol F
D
P
S
UK
Suppository Bisacodyl D
P
S
UK
Gel Diazepam F
D
P
S
UK
Suppository Diazepam D
P
Suppository Sodium Diclofenac F
D
UK
Suppository Glycerine F
D
P
S
UK
Rectal solution Glycerine P
S
Suppository Ibuprofen D
P
a All listed drug products are human prescription drug label except those containing ‘OTC’
AEMPS, Pharmanet-Bund, and Infarmed search, March, 8th 2013).on the market, a restriction of use was applied on nine of them (i.e. for
children over 30 months only). The evolution of the French market
can be explained by three main reasons: economic withdrawal, legal
withdrawal, and restriction of use due to active ingredients being
deemed inappropriate for young children. These restrictions of use
were implemented in France in 2011. It was also noticed during this in-
vestigation that somewithdrawals also took place from the Spanish and
Portuguese market, at approximately the same time around 2010.
These changes highlight the fact that national health agencies have
taken into account some speciﬁc paediatric needs.3.3. Paediatric rectal forms cited in the scientiﬁc literature: a scoping
exercise
The keywords used for this Scopus search were [suppository OR rec-
tal] AND [children OR paediatric]. Out of the 8942 references proposed
by Scopus, were included only articles written in English (6664 refer-
ences)where a rectal dosage formwasmentioned (either for formulation
work on rectal dosage forms or for clinical studies — 128 references).
More thanhalf of the literature references (69 out of 128) on rectal dosage
forms for paediatrics were published since 2000 showing the interest of
this route of administration to treat children.
The scientiﬁc literature also shows a clear preference for supposito-
ries, as 84% of publications on paediatric rectal dosing refer to thisl (P), Spain (S), and United Kingdom (UK).
Dose Indicationsa, age
80, 100, 150, 200, 300 mg (OTC) Analgesic, antipyretic
75, 125, 250, 500 mg
75, 125, 250, 500 mg
125, 250 mg (OTC)
60, 125, 250 mg
10 mg Laxative
10 mg
10 mg (OTC)
5 mg
5, 10 mg Epilepsy
5, 10 mg
5, 10 mg
10 mg
5, 10 mg
10 mg Epilepsy
5, 10 mg
25 mg NSAID
12.5, 25, 50 mg
12.5, 25, 50 mg
1.25 g (OTC) Laxative
0.85, 1.5, 2 g (OTC)
0.686, 1, 1.1 g (OTC)
Up to 2 g (OTC)
1 g (OTC)
NA (OTC) Laxative
NA (OTC)
75, 150 mg NSAID, analgesic, antipyretic
75, 125, 150 mg
over-the-counter drug products (57 references selected after an ANSM, Thériaque, eMC,
Table 6
Evolution of the French market for paediatric rectal forms between 1990 and 2012.
Therapeutic class Drug Marketed drug productsa
listed in 1990
Marketed drug productsa
listed in 2012
Modiﬁcation
Analgesic Paracetamol 2 3 1 new reference
Aspirin + Phenobarbital 2 0 Withdrawn in 1997
Glafenine 1 0 Withdrawn in 1992
Paracetamol + Promethazine 1 1 From 2 to 5 years
Anti-emetic Metoclopramide 1 0 Withdrawn in 2012
Anti-infectious Clofoctol 1 0 Withdrawn in 2005
Laxative Gelatine + Glycerine 1 1 None
Mannitol 2 0 Withdrawn in 1992
Sodium bicarbonate + Potassium bitartrate 1 1 None
Sorbitol 1 1 None
Glycerine 1 2 1 new reference
Ox bile 1 0 Withdrawn in 1992
NSAIDs Diclofenac 1 1 None
Niﬂumic acid 1 1 None
Naproxen 1 0 Withdrawn in 1997
Respiratory Bamifylline 1 0 Withdrawn in 2003
Theophylline 1 0 Withdrawn in 2010
Citral + Guaiacol + Terpineol + Pine + Thyme 1 1 Withdrawal of infant dosage in Feb. 2012. Restriction
of use: only for children over 30 months.Eucalyptol + Guaiacol + Pine + Amyleine HCl 1 1
Sodium teonate + Eucalyptus 1 1
Sodium teonate + Eucalyptus + Paracetamol 1 1
Guaifenesine + Eucalyptol + Bismuth 1 1
Niaouli + Grindelia + Gelsenium 1 1
Guaifenesine + Eucalyptol + Camphor 1 1
Bismuth + Eucalyptol + Guaiacol + Camphor 0 1
Turpentine 1 1
Turpentine + Diprophylline 1 1
Terpine + Pine + Niaouli + Eucalyptus 1 0 Withdrawn in 2012
a Multiple doses may exist for each drug product listed in this table.
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(7%), enemas (6%), and gels (3%).
Suppositories are a versatile rectal dosage form as they can be used
for all the main therapeutic indications listed in Table 7. On the other
hand, alternative rectal dosage forms are mainly used in hospitals for
premedication, anaesthesia or postoperative pain management in the
case of rectal solutions [58–67] and gels [68], and for preparation of
the colon before colonoscopy with enemas [69]. Exceptions are the
use of Valproate retention enema to treat epilepsy [70], and gels or sys-
tems that form gel in situ [71–73]. This latter type of novel dosage form
will be discussed later.
Table 8 shows the top 6 pharmaceutical active ingredients formulat-
ed in rectal dosage forms.
Most of the time paediatric suppositories are used for systemic ef-
fect. Paracetamol [74–96] and Sodium Diclofenac [97–113] are the
two main active ingredients studied in the literature and are as well
the two main drugs available on the market. Apart from Sodium
Diclofenac, other non-steroidal anti-inﬂammatory drugs are also formu-
lated in suppository form as for example: Ibuprofen [76,114], Niﬂumic
acid [93,115], Aspirin [116,117], Ketoprofen [118–121], Mephenamic
acid [122], Indomethacin [71,72,123], Suprofen [96], Nimesulide [73],
and Tinoridine [124]. These suppositories are intended to treat (post-
operative) pain, migraine, and fever.Table 7
Therapeutic indications of paediatric rectal dosage forms.
Therapeutic indication % of citations
Analgesic 37
Anti-infectives 18
Laxatives 10
Premedication 10
Antipyretic 9
Anti-emetic 6
Anaesthetic 4
As found in the scientiﬁc literature from 1975 to 2013 (128 publications
selected after a Scopus search, February, 26th 2013.)Anothermain indication of paediatric suppositories for systemic effect
is anti-infectives (Ampicillin [125–136], Ceftizoxime [137–139], and
Azithromycin [140,141]) and in some antimalarial drugs (Artesunate
[29,30,38,142], Artemether in association with Azithromycin [143], and
Artemisinin [30]). It should be noted that all twelve references on the
in vivo effect of Ampicillin suppositories were published in 1983 by
Japanese researchers in the same volume of the Japanese Journal of
Antibiotics. Suppositories are a dosage form of choice to administer the
high doses required for antibiotics, minimising the need for multiple
oral dosing to reach the desired drug level [4]. In addition, suppository
formulations avoid the problem of poorly palatable antibiotics that are
difﬁcult to administer to children [144].
Suppositories are also used to treat febrile seizures and epilepsywith
Diazepam [145–147] or Valproate [70], nephropathic cystinosis with
Cysteamine [148], asthma with Aminophylline [149], cough with
terpenic derivatives [150] or Ephedra decoction (a Traditional Chinese
Medicine) [151], and pain with Pentazocine [152] or migraine with Er-
gotamine tartrate [117].
Suppositories can also be the form of choice for indications where
the oral route is not usable. This is the case of anti-emetic drugs such
as: Dimenhydrinate [153–156], Promethazine [157], Domperidone
[158,159], and Metoclopramide [159].
Like rectal solutions, suppositories are used in hospital for
premedication (Midazolam in association with Famotidine [160],
Bromazepam [161,162], Diazepam [163–165], Pentobarbital [166],
Chloral hydrate [162]), postoperative pain management (Codeine
[167] alone or in association with Paracetamol [168]).
Suppositories can also be used for local effects such as laxative in
substitution to enema, with the use of active ingredients like glycerine,
bisacodyl or a combination thereof [169–180], or Mesalamine for the
treatment of ulcerative proctitis [181,182].
3.4. Suppositories: considerations for paediatric dosing
Rectal dosage forms, as described by the European Pharmacopoeia,
can be suppositories, capsules, solutions, suspensions, ointments, creams,
Table 8
Active ingredients formulated in paediatric rectal dosage forms.
Active Pharmaceutical Ingredient % of citations
Paracetamol 20
Sodium Diclofenac 15
Ampicillin 10
Diazepam 6
Artesunate 3
Dimenhydrinate 3
As found in the scientiﬁc literature from 1975 to 2013 (128 publications selected
after a Scopus search, February, 26th 2013).
42 V. Jannin et al. / Advanced Drug Delivery Reviews 73 (2014) 34–49gels, foams, and tampons (Table 2). Themost commonly used rectal form
is by far suppositories as demonstrated by the commercial drug products
and literature review aforementioned.
Suppositories for paediatric dosing are generally torpedo-shaped
dosage forms weighting 1 g. There are also novel stick-shaped supposi-
tories with a line of breakability to divide the dosage form in two halves
which allow reducing the dose for smaller children. Theweight of 1 g for
paediatric dosing [4] facilitates the insertion of the smaller suppository
in the child's rectumwhile allowing having an object easily manipulat-
ed by the parent or care-giver. Paediatric suppository doses are general-
ly adjusted from adult doses based on body weight. Taking into account
the difference of available surface for absorption in the rectum (Table 1)
would certainly be a better option.
3.4.1. Choice of the excipient
Paediatric suppositories are generally composed of the same excipi-
ents as the adult dosage forms, that is to say, either composed of:
- fatty bases (hard fat or cocoa butter that melts at the temperature of
the rectum) or
- water-soluble bases (polyethylene glycol (PEG) or glycerinated
gelatine that dissolves in the rectum).
The choice between these two types of suppository masses depends
on the physicochemical properties of the active ingredient and the de-
sired release proﬁle [4]. Formulators generally choose to disperse
drugs in suppository masses where it is not soluble, to facilitate the re-
lease of the drug from the dosage form. Hence, water-soluble drugs are
formulatedwith fatty bases and lipophilic drugs in water-soluble bases.
Since most of the active pharmaceutical drugs used by the rectal route
are water-soluble (Biopharmaceutics Classiﬁcation System — BCS class
I) such as Paracetamol, Diazepam, Ketoprofen, Midazolam, and Aspirin,
or are weak acids showing limiting dissolution by the oral route (BCS
class II) but which are soluble in the rectum for example Sodium
Diclofenac, Ibuprofen and Indomethacin [183], the choice of fatty
bases is most of the time the best way to formulate suppositories.
Suppositories composed of fatty bases should melt at a temperature
near to body temperature (37 °C) and the resulting melt should cover
the rectum with a thin ﬁlm of fat where the drug can diffuse out and
reach the rectummucosa. Among fatty bases, hard fat is the most com-
mon suppository mass used in Europe (mainly Southern and Eastern
Europe including Russia), North Africa, Middle East, People's Republic
of China, and Japan.
Various types of hard fats are available on themarketwith twomain
characteristics: their drop point ranging from 32 to 45 °C [4], and their
hydroxyl value ranging from less than 3 to 50 mg KOH per gram of fat.
The main commercial names for hard fats are Suppocire® (Gattefossé)
andWitepsol® (Sasol). The drop point (alternative method to evaluate
themelting properties of fat) of suppositorymasses varies around 37 °C
in order to allow the incorporation of all types of drugs. As a matter of
fact, drugs which are soluble in the suppository mass will induce a de-
crease of the melting temperature of the excipient. Hence a hard fat
with a drop point higher than 37 °C should be chosen to obtain, after in-
clusion of the drug, a formulation which softens/melts between 36 and
37 °C. On the contrary, for drugs which are not soluble in the excipientmass and possess a high dose, the viscosity of themelt can be too high to
allow an adequate softening at the rectum temperature. In order to re-
duce the viscosity at this temperature, a hard fat with a drop point
lower than 37 °C is classically chosen. Hard fats also possess a large
range of hydroxyl values depending on the number of free hydroxyl
groups in the excipient mass. These free hydroxyl groups come from
partial glycerides i.e. monoglycerides and diglycerides, and also from
free glycerol. Hard fats with high hydroxyl value generally crystallise
faster than other types of hard fats because their content of monoglyc-
erides is higher and these molecules present a solidiﬁcation tempera-
ture higher than the main components of hard fat: triglycerides. These
free hydroxyl groups also impact the ability of the suppository mass to
interact withwater and hence can increase the dissolution rate of active
ingredient.
These lipophilic excipients are derived from natural vegetable oils
and arewell tolerated by the rectal mucosa [184]. However, one publica-
tion has suggested that hard fat bases with high hydroxyl value could be
irritant to the rectal mucosa [185]. Hard fats also conform to the recom-
mendations for paediatric excipients because they allowminimisation of
the number of excipients (most of the time only one suppositorymass is
used); risk additives can be avoided (e.g. colouring agent, antimicrobial
preservatives, sweetening agents, taste-masking agents or solubility en-
hancers), and also they do not cause religious concerns (in opposition to
rectal capsules composed of gelatine) [186]. However, some fatty bases
may contain some additives such as phospholipids (to accommodate
for high dose of powdered drug), monoglycerides (to accelerate drug re-
lease), andnon-ionic surfactant (polysorbates to facilitate the emulsiﬁca-
tion of hydrophilic liquid drug into the fatty base) preferred to ionic
surfactants which are often irritant to the rectal mucosa.
The cost of goods for fatty bases is relatively low for excipients, in
comparison to other excipients classically used in oral dosage forms.
Hard fats are considered as global commodities because the raw mate-
rials are easily available at low price and the processes needed to trans-
form them into fatty bases are simple and non-proprietary. The price of
suchmaterials is about 10-fold lower than functional excipients for oral
dosage forms.
Due to climate constraints, PEGs can be used as a substitute to
hard fats in tropical regions such as Africa. This mass can be irritating
to mucosa by causing stinging [187] or even cause hypersensitivity
(particularly for PEGswith lowermolecularweights) [188]. For this rea-
son PEGs are less adapted to paediatric dosing than natural hard fats.
For these regions other solid alternatives recommended include rectal
soft gelatine capsules with a lubricating coating. This is the case in the
South American market for example. These rectal forms composed of
water-soluble bases should dissolve freely in the rectum liquid at 37 °C.
Regarding rectal solutions, water-soluble drugs – as powders or for-
mulated in rectal tablets – are often extemporaneously dissolved in
aqueousmedia such as distilledwater, sterile water, or sodium chloride
solution as reported for anaesthetic drugs in the literature. However,we
found on the market a Diazepam rectal solution containing excipients
less adapted to children like ethanol or benzyl alcohol [189]. The rectal
solution is administeredwith an appropriate preﬁlled-syringe equipped
with a lubricated catheter to facilitate introduction in the children's
rectum.
3.4.2. Manufacturability
Themanufacture of suppositories is a four-step process including the
preparation of raw materials, mixing of the drug with the melted mass,
moulding of suppositories in blisters, and subsequent crystallisation of
the formulation. Some alternative methods to moulding are described
in the literature andwill be presented in the following section dedicated
to the future of rectal dosage forms. Even if themoulding process seems
straightforward, some steps and parameters should be looked at
closely to avoid major drawbacks for paediatric dosing, such as non-
homogeneity or crystallisation of the drug on the surface of the dosage
form.
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above its statedmelting point to allow a completemelting of all crystals.
If the drug is soluble in the suppository mass, it should be dissolved in
the appropriate excipients. If not, the particle size of the drug should
be controlled [45] because it can affect the viscosity of the mixture
(small particles in suspension tend to increase the viscosity of the
medium) and the homogeneity of the dosage form. The mixing of the
drug with the melted excipient should provide for a homogeneous
system. The moulding step of the mixture should be conducted at the
appropriate temperature to allow for a rapid crystallisation of the
mass and hence limit the ability of the drug to precipitate at the bottom
of the blister. This temperature is determined by thermorheology and
corresponds to the temperature where the viscosity of the melt starts
to sharply increase. Moulding at the lowest temperature possible will
also facilitate the crystallisation of the suppository and avoid drawbacks
caused by a too high difference between pouring and crystallisation
temperatures: polymorphism (fat blooming on the surface of supposi-
tories), cracks (contraction of lipid during rapid solidiﬁcation), or sedi-
mentation of the drug. This latter step is particularly important for
paediatric suppositories because it can affect the weight (formation of
chimney at the base of the suppository), and the homogeneity of
mass, which can be problematic for scored suppositories.
In some developing countries, suppositories can still be moulded
manually within metal moulds. The same manufacturing process can
be implemented as for industrial process with the addition of a scrap-
ping step after solidiﬁcation of the suppository mass to remove the
extra-mass of mixture. This manual process is also used in some hospi-
tals for extemporaneous compounding of drugs not commercially avail-
able as paediatric rectal forms on the market. Metallic moulds available
on themarket do not allowproducing suppository of less than 1 g. In ad-
dition, producing smaller dosage forms will compromise the ability of
these suppositories to conform to pharmacotechnical tests.
3.4.3. Pharmacotechnical testing of suppositories
The European Pharmacopoeia (EP) is the only Pharmacopoeia de-
scribing some speciﬁc pharmacotechnical tests for rectal dosage forms
such as suppositories and vaginal pessaries [45]. These tests aim to ver-
ify the ability of the dosage form to quickly disintegrate in contact with
water (forwater-soluble bases [190]) or to soften at a temperature close
to the rectum temperature (for fatty bases [191]) in order to release the
active ingredient [192]. The uniformity of mass [193] and content [194]
is needed for these single-dose preparations. The uniformity of drug re-
partition within the suppository is also particularly important for adult
doses which are sometimes cut in halves to accommodate for paediatric
dosing. This is an unlicensed use that can take place in somehospitals. In
most cases the suppository is cut in its length in order to have a homo-
geneous content of drug even if the drughas sedimented in the tip of the
dosage form [195]. However, recasting adult suppositories into moulds
of smaller size (generally 1 g) is a better option to ascertain a homoge-
neous repartition of the drug within the dosage form. Interestingly,
some forms on themarket already exist as scored stick-shaped suppos-
itories, in order to accommodate for two doses (Fig. 1): Paracetamol
scored suppositories at 100mg, andMorniﬂumate scored suppositories
at 400 mg (dividable in 200 mg halves), for example [88].
Additional tests, actually not described in any Pharmacopoeia, are
classically used to assay suppositories such as resistance to crushing,
slip melting temperature or appearance evaluation.
4. Paediatric clinical studies: a 10-year overview
This section focuses on clinical trials conducted in children within
the last ten yearswith severalwell-knowndrugs. In brief, it collates pae-
diatric clinical studies focusing on the comparison of the rectal route
with other routes of administration, the determination of paediatric rec-
tal doses and the evaluation of drug associations. These clinical studiesare listed by indication: analgesics/antipyretics, antiepileptics, and anti-
malarial drugs.
4.1. Analgesics, antipyretics and NSAIDs
Paracetamol was used in several clinical trials as an analgesic in pre-
and post-operative painmanagement for minor surgery, sometimes as-
sociated with Codeine, or in chronic diseases [79–81,168,196,197], with
good results. Paracetamol administered by the rectal route is less efﬁ-
cient than the intravenous route in the case of pain management after
major surgery, [91], and it must not be used in the speciﬁc case of new
born after assisted vaginal delivery [198]. However, it is recommended
as an antipyretic in emergency cases [199] and the rectal route is as ef-
ﬁcient as the oral route [40]. Ameta-analysis compares the oral and rec-
tal routes for reducing fever. It concluded by the equivalence of these
two routes andmay change the point of view of The American Academy
of Pediatrics, whose recommendation was, so far, to refrain rectal
administration of Paracetamol to children [82].
Diclofenac is used as an analgesic in pre- and post-operative pain
management after surgery and shows good efﬁcacy by rectal adminis-
tration alone, or in association with other drugs [97,112,200].
Ketoprofen administered by the rectal route is a good alternative to
the intravenous or oral routes [118,201].
Midazolam can reduce, or even avoid, the use of general anaesthesia
for dental treatments [202].
Mesalamine suppository is a safe and efﬁcient treatment of ulcera-
tive proctitis for children [181].
4.2. Antiepileptics
Diazepam administration by the rectal route is sure, efﬁcient and
better than the nasal route [37,145,146].
The use of Paraldehyde by the rectal route is efﬁcient in the case of
prolonged tonic–clonic convulsions [203].
4.3. Antimalarial drugs
Malaria is referenced as a tropical disease with prevalence in chil-
dren under 5 years of age [204]. Numerous clinical trials on children
were conducted lately with old active pharmaceutical ingredients.
This high number of studies can be explained by the need to have dos-
age forms that can be easily administered in case of emergency, the
prevalence of this pathology, and the involvement of many non-
governmental organizations. Three main conclusions can be drawn
from these clinical trials.
- Rectal administration can either be usedwith only onedrug in emer-
gency [55,205–207], or as a long-term treatment [208–210]. The
rectal form of Artesunate was also tested in association with
Meﬂoquine and this allowed improving the efﬁciency, and/or short-
ening the treatment [211–213]. Rectal diazepam was tested as an
anti-convulsing drug in the cases of children with severe Falciparum
malaria and convulsions, but its efﬁciency seems lower than paren-
teral administration [214].
- The use of rectal dosage forms allowed the treatment of children in
rural areas where the parenteral administration of drug is not possi-
ble. Some clinical studies were performed to compare the rectal and
parenteral routes, either using the same drug [35,215–217] or two
different active substances. In every case the rectal route has either
given comparable or greater efﬁciency [218–220].
- Two studies concluded to the importance of Artesunate as pre-referral
treatment of severe childhoodmalaria and on the cost effectiveness of
the rectal form [221,222]. Another study demonstrated the urgent
need to develop an association of twodrugs: antimalarial and antibac-
terial in the same rectal dosage form to decrease the cost of the treat-
ment and avoid many deaths (up to 400,000) [223].
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drugs by the rectal route is very effective (especially in the case of emer-
gencies), well adapted to endemic areas, able to be used at home by any
care giver, and cost effective. The association of antimalarials and anti-
bacterials seems to be possible; nevertheless there are no recent studies
on antibiotic rectal forms, despite some studies initiated in the 1990s
[224]. This association was at the same time the most efﬁcacious, the
most cost effective, and also well adapted to emergency situations in
cases with a lack of diagnostics.
5. The future
Research on paediatric rectal forms consists presently in the improve-
ment of actual forms (especially suppositories and gels), and in the devel-
opment of dosage forms classically used in other routes such as tablets for
example. Obviously these so-called classical forms must be adapted to
the speciﬁcities of the rectal route (e.g. small amount of liquid).
5.1. In vitro and preclinical studies
5.1.1. Thermosensitive and/or mucoadhesive gels
In order to solve some drawbacks of conventional solid supposito-
ries, various formulation strategies have been developed such as
thermosensitive and mucoadhesive in situ gel systems. The combina-
tion of thermosensitive andmucoadhesive properties in a single formu-
lation presentsmany advantages. First, the thermosensitive preparation
is liquid at ambient temperature which facilitates its preparation and
handling, but also eases its spreading in the rectal cavity where it gels
at the body temperature. Secondly, in the rectal cavity, the development
of mucoadhesive properties helps to maintain the hydrogel for a
prolonged period of time and allows complete drug release, thus
favouring systemic absorption.
Over the last two decades, thermosensitive polymers and hydrogels
have focused a growing interest in the pharmaceutical ﬁeld. Depending
on their composition, the sol–gel transition temperature can be adjust-
ed around 37 °C for pharmaceutical applications [73,225–231].
5.1.2. Suppositories
Some new suppository developments are on-going on three main
topics:muco-adhesiveness, controlling drug release, and improving sta-
bility/storage at high-temperature.
5.1.2.1. Muco-adhesiveness. The addition of mucoadhesive excipients in
suppository formulations permits the adhesion of the dosage form in
the lower rectum and hence avoids the drainage of the drug by the
upper haemoroidal veins (leading to hepatic ﬁrst pass effect). Carbomer
(Carbopol®) is described in several studies for the development of such
mucoadhesive properties. For example, the association of this polymer
(2% of the 934-P grade) to hard fat allows obtaining Ramosetron sup-
positories with efﬁciency comparable to the intravenous administration
of the drug [230]. Furthermore, this percentage of carbomer did not in-
duce irritation of the rectal mucosa of rabbits.
Double-phased mucoadhesive suppositories were also described in
two other formulations containing either Lidocaine or Diclofenac as ac-
tive ingredients. These studies were performed on rats and rabbits [232,
233]. Double-phased suppositories consist of a mucoadhesive front
layer containing wax and a mucoadhesive terminal layer containing
the drug. The anchoring phase (adhesion and spatial conﬁguration of
the suppository within the rectum) strictly limits the absorption of the
drug in the lower rectum and the formulation of the terminal layer
modulates drug release properties. This double-phased suppository
may be useful for improving bioavailability of drugs with signiﬁcant
ﬁrst-pass effect.
5.1.2.2. Controlling drug release. The addition of surfactants in supposito-
ry formulations can also help increase drug release provided that theyare not irritant to rectal mucosa [234]. Surfactants such as polysorbate
80 (2%) and sodium lauryl sulphate (0.75%) increase the dissolution
rate of Salbutamol from suppositories. However, sodium lauryl sulphate
could cause greater damage onmucosa thanpolysorbate 80because it is
an anionic surfactant [235]. The addition of rectal absorption enhancer,
like snail mucin, was also tested with Insulin in rats [236].
Sustained-release hollow-type (SR-HT) suppositories are a new plat-
form developed with sodium alginate (Alg-Na), sodium polyacrylate
(PANa) or polyacrylate-PANa co-polymer (PA-PANa) as gelling agents.
The gelling agent is either combined with the drug inside the hollow
part of the suppository ormixedwith the shell. A study of SR-HT contain-
ing Aminophylline conducted on rabbits showed that these suppositories
could be used for rectal administration of various drugs needing a
prolonged plasma concentration [237].
Hollow-type suppositories containing 10mg ofMorphine in sodium
hyaluronate solutions of various viscosities were prepared. It appears
that the selection of the relevant viscosity of sodium hyaluronate solu-
tion contributes to the improvement of Morphine bioavailability after
rectal administration to rabbits [238]. This model has been studied
with other active pharmaceutical ingredients and/or excipients and
gave similar improvement of drugs bioavailability [239–241].
Self-emulsifying suppositories were developed for β-Artemether
and Indomethacin [242,243]. These forms induce sustained release for
β-Artemether in comparison to PEG suppository, and a similar increase
of bioavailability of Indomethacin after oral and rectal administration.
5.1.2.3. Improved stability at high-temperature. Suppositories able to
withstand tropical climates canbe developedwith excipients possessing
melting points above 50 °C. Such suppositories can be formulated with
high-molecular PEG such as PEG 4000 and PEG 1500. The use of these
water-soluble bases with Azithromycin produced suppositories with
good bioavailability in rabbits when compared to other rectal forms
(hard gelatin capsules, gels and oily suspension) [140].
5.1.3. Other forms
Other systems are being developed or adapted to the rectal route:
- New disintegrating excipients used for oro-dispersible tablets such as
crospovidone or sodium croscarmellose are able to disintegrate the
dosage form with minimal amounts of liquid (2 to 3 mL). These new
excipients could also be used for recto-dispersible tablets [244]. It
was used to formulate two drugs (Artesunate and Azithromycin) for
emergency treatment of Malaria (Larrouture, D. et al. Development
of antimalaric-antibiotic association in a fast dispersible tablet using
rectal route. 3rd Conference of the European Paediatric Formulation
Initiative (EuPFI), Strasbourg, France, 2011).
- Mucoadhesive polymers allow production of bio-adhesive micro-
spheres, whose properties can improve the in situ stabilisation, en-
hance the spreading of the formulation on mucosa, and/or modify
the drug release [245–247].
- Emulsions could be an alternative to rectal form in order to modify
drug release as demonstrated by some studies with Diazepam
[248–250].
The tolerability of these oral excipients may be extrapolated to the
rectal route as this mucosa is more resistant than the upper gastrointes-
tinal one because of its limited surface and the presence of mucus.
However safety of excipients, especially if novel, in children is para-
mount and should be checked with appropriate studies ﬁrst, prior to
promoting their use widely.
5.2. Vaccination by the rectal route
Recent publications have shown the interest of the rectal route for
mucosal or systemic vaccination. The mucosal route is mainly used for
vaccination because most infections affect or start from a mucosal sur-
face. In these infections, topical application of the vaccine is often
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of appropriate adjuvants such as toxins or cytokine [253,254] can in-
crease the efﬁciency of the rectal vaccination. Furthermore, the rectal
route offers additional advantages, especially in developing countries,
such as a reduced risk of viral transmission (no need of injections),
less side effects, and the possibility to administer the drug productwith-
out medical training [255].
Vaccination by the rectal routewas tested for tuberculosis and it was
as efﬁcient as the parenteral route in mice, guinea pigs and macaques
[255]. This route was also experimented for Herpes vaccination with
good results [253,256,257]. The main area of research for mucosal
vaccination is HIV, an infection transferred by mucosal contamination
(vaginal or rectal). The combination of local and systemic protection
seems to be appropriate [254,258] and the FDA presents prophylaxis
strategies using the rectal route against HIV infection [259]. These inves-
tigations give very encouraging and positive results in animals, but have
not yet been tested in humans. Even if this type of vaccination will face
the same socio-ethical barriers as classical rectal dosage forms, children
should be included in future positive development or rectal vaccination
research programmes where relevant.
6. Conclusions
The rectal route is usually better known for its disadvantages than
for its advantages. The main disadvantages are the introduction of a
solid unit in the rectum (leading to poor acceptability and compliance),
the low absorption capacity of the lower rectum to some drugs, and the
high inter-individual variability of the drug bioavailability mainly de-
pending on how the dosage form is inserted.
Rectal dosage forms present many advantages, especially in devel-
oping countries, because of their low cost, the possible administration
of the form without any medically trained person (in contrast to intra-
venous route for example) and the possibility to dose drug product in
emergencies even to unconscious or vomiting children. In the case of
emergency administration there may be lower psychological and social
barriers because of the seriousness of the situation.
Finally mindsets may be changing regarding the dosing of drugs rec-
tally to children, as some of themain disadvantages of suppositories are
being solved: the variable absorption of drugs due to variable insertion/
retention of the dosage forms can be controlled by adapted formulation
(muco-adhesive dosage forms) or appropriate devices. Also some pae-
diatric clinical studies throughmeta-analysis have recently demonstrat-
ed the equivalence of rectal dosage forms versus oral dosage forms like
in the case of Paracetamol. In order to enable the use of this promising
route for the treatment of children in the 21st Century, some effort
should be focused on marketing, informing and educating parents and
care givers on the beneﬁts of these novel rectal dosage forms. Their
comprehension should ensure the acceptability, compliance, and cor-
rect usage of the rectal forms.
References
[1] J.M. Aiache, R. Renoux, D. Fistre, History of the suppository form [Historique de la
forme suppositoire], in: B. Glas, C.J. de Blaey (Eds.), Rectal Therapy: Proceedings
of the Symposiumon theAdvantages and Problems Encountered in Rectal Therapy,
J.R. Prous Publishers, Barcelona, 1984, pp. 5–8.
[2] N.J.B.G. Guibourg, N.E. Henry, Pharmacopée Raisonnée ou Traité de Pharmacie Pra-
tique et Théorique, Mequignon-Marvis, Père et Fils, Paris, 1841.
[3] J.T. Gwathmey, Rectal administration of evipal soluble. A safe, reversible and con-
trollable preanesthetic medication a preliminary report, Am. J. Surg. 32 (1936)
411–416.
[4] J.H. Rytting, J.A. Fix, Drug delivery— rectal route, in: J. Swarbrick, J.C. Boylan (Eds.),
Encyclopedia of Pharmaceutical Technology, Marcel Dekker, Inc., New York, 2002,
pp. 932–944.
[5] H.E. van, A.G. de Boer, D.D. Breimer, Pharmacokinetics of rectal drug administra-
tion, part I. General considerations and clinical applications of centrally acting
drugs, Clin. Pharmacokinet. 21 (1991) 11–26.
[6] ICH harmonised tripartite guideline, clinical investigation of medicinal products in
the pediatric population — E11 [on line], Available on: http://www.ich.org/ﬁleadmin/Public_Web_Site/ICH_Products/Guidelines/Efﬁcacy/E11/Step4/E11_
Guideline.pdf (consulted 3-4-2013).
[7] Guideline on the investigation ofmedicinal products in the termand pretermneonate
(CHMP/PDCO)— EMEA/536810/2008 [on line], Available on: http://www.ema.euro-
pa.eu/docs/en_GB/document_library/Scientiﬁc_guideline/2009/09/WC500003750.
pdf (consulted 22-3-2013).
[8] Alternative routes of drug administration—advantages and disadvantages (subject
review), American Academy of Pediatrics Comm. Drugs Pediatr. 100 (1997)
143–152.
[9] Committee for Medicinal Products for Human Use (CHMP), reﬂection paper: for-
mulations of choice for the paediatric population (EMEA/CHMP/PEG/196810/
2005) [on line], Available on: http://www.ema.europa.eu/docs/en_GB/document_
library/Scientiﬁc_guideline/2009/09/WC500003782.pdf (consulted 22-3-2013).
[10] R.C. Woody, E.S. Golladay, S.C. Fiedorek, Rectal anticonvulsants in seizure patients
undergoing gastrointestinal surgery, J. Pediatr. Surg. 24 (1989) 474–477.
[11] J. den Hertog, E. van Leengoed, F. Kolk, L. van den Broek, E. Kramer, E.J. Bakker, E.
Bakker-van Gijssel, A. Bulk, F. Kneepkens, M.A. Benninga, The defecation pattern
of healthy term infants up to the age of 3 months, Arch. Dis. Child Fetal Neonatal
Ed. 97 (2012) F465–F470.
[12] L.T. Weaver, G. Ewing, L.C. Taylor, The bowel habit of milk-fed infants, J. Pediatr.
Gastroenterol. Nutr. 7 (1988) 568–571.
[13] S.M. Mugie, C. Di Lorenzo, M.A. Benninga, Constipation in childhood, Nat. Rev.
Gastroenterol. Hepatol. 8 (2011) 502–511.
[14] D.M. Mota, A.J. Barros, A. Matijasevich, I.S. Santos, Longitudinal study of sphincter
control in a cohort of Brazilian children, J. Pediatr. (Rio. J.) 86 (2010) 429–434.
[15] Population and human development, in: World Ressource Institute (Ed.), World
Resources 1992–1993: A Guide to the Global Environment—Toward Sustainable
Development, University Press, Oxford, 1992.
[16] O.M. Wrong, Deﬁnitions and history, in: J.H. Cummings, J.L. Rombeau, T. Sakata
(Eds.), Physiological and Clinical Aspects of Short-Chain Fatty Acids, Cambridge
University Press, Cambridge, 2004, pp. 5–8.
[17] J.P. Jantzen, P. Diehl, Rectal administration of drugs. Fundamentals and applications
in anesthesia, Anaesthesist 40 (1991) 251–261.
[18] W. Bitterman, R.J. Spencer, K.A. Huizenga, R.G. Shorter, Contact pH of rectal mucosa
in humans and dogs, Dis. Colon Rectum 12 (1969) 96–98.
[19] J.P. Jantzen, I. Tzanova, P.K. Witton, A.M. Klein, Rectal pH in children, Can. J.
Anaesth. 36 (1989) 665–667.
[20] C. Turner, T.N. Aye Mya, P. Turner, F. Nosten, N.J. White, Rectal pH in well and un-
well infants, J. Trop. Pediatr. 58 (2012) 311–313.
[21] Development of paediatric medicines: points to consider in formulation, WHO Ex-
pert Committee on Speciﬁcations for Pharmaceutical Preparations, , WHO Press —
World Health Organization, Geneva, 2012. 179–226.
[22] S. Lundeberg, P. Hatava, M. Lagerkranser, G.L. Olsson, Perception of pain following
rectal administration of morphine in children: a comparison of a gel and a solution,
Paediatr. Anaesth. 16 (2006) 164–169.
[23] S. Winnick, D.O. Lucas, A.L. Hartman, D. Toll, How do you improve compliance?
Pediatrics 115 (2005) e718–e724.
[24] Digital bowel stimulator and suppository inserter [on line], Available on: https://
www.ncmedical.com/item_389.html?item_num=NC28704 (consulted 15–3–
2013).
[25] B. Jensen, L. Matsson, Oral versus rectal midazolam as a pre-anaesthetic sedative in
children receiving dental treatment under general anaesthesia, Acta Paediatr. 91
(2002) 920–925.
[26] R.L. Hinton, A. Auwun, G. Pongua, O. Oa, T.M. Davis, H.A. Karunajeewa, J.C. Reeder,
Caregivers' acceptance of using artesunate suppositories for treating childhood
malaria in Papua New Guinea, Am. J. Trop. Med. Hyg. 76 (2007) 634–640.
[27] F.A. Kaona, M. Tuba, A qualitative study to identify community structures for man-
agement of severe malaria: a basis for introducing rectal artesunate in the under
ﬁve years children in Nakonde District of Zambia, BMC Public Health 5 (2005) 28.
[28] E.A. Makundi, H.M. Malebo, P. Mhame, A.Y. Kitua, M. Warsame, Role of traditional
healers in the management of severe malaria among children below ﬁve years of
age: the case of Kilosa and Handeni Districts, Tanzania, Malar. J. 5 (2006) 58.
[29] S.O. Sam-Wobo, O.A. Agbeyangi, U.F. Ekpo, O.A. Akinloye, C.F. Maﬁana, M.A.
Adeleke, Rectal artesunates, their utilization, and parental perception in the man-
agement of malaria in children from Abeokuta, southwestern Nigeria, Vector
Borne Zoonotic Dis. 12 (2012) 151–155.
[30] D.O. Simba, M. Warsame, O. Kimbute, D. Kakoko, M. Petzold, G. Tomson, Z. Premji,
M. Gomes, Factors inﬂuencing adherence to referral advice following pre-referral
treatment with artesunate suppositories in children in rural Tanzania, Trop. Med.
Int. Health 14 (2009) 775–783.
[31] D.O. Simba, D.C. Kakoko, M. Warsame, Z. Premji, M.F. Gomes, G. Tomson, E.
Johansson, Understanding caretakers' dilemma in deciding whether or not to ad-
here with referral advice after pre-referral treatment with rectal artesunate,
Malar. J. 9 (2010) 123.
[32] M.A. Thera, F. Keita, M.S. Sissoko, O.B. Traore, D. Coulibaly, M. Sacko, V. Lameyre, J.P.
Ducret, O. Doumbo, Acceptability and efﬁcacy of intra-rectal quinine alkaloids as a
pre-transfer treatment of non-per os malaria in peripheral health care facilities in
Mopti, Mali, Malar. J. 6 (2007) 68.
[33] S.A. Colbert, D. O'Hanlon, O. McAnena, N. Flynn, The attitudes of patients and
health care personnel to rectal drug administration following day case surgery,
Eur. J. Anaesthesiol. 15 (1998) 422–426.
[34] N. Seth, N.E. Llewellyn, R.F. Howard, Parental opinions regarding the route of adminis-
tration of analgesic medication in children, Paediatr. Anaesth. 10 (2000) 537–544.
[35] H. Barennes, D. Kailou, E. Pussard, J.M. Munjakazi, M. Fernan, H. Sherouat, A. Sanda,
F. Clavier, F. Verdier, Intrarectal administration of quinine: an early treatment for
severe malaria in children? Sante 11 (2001) 145–153.
46 V. Jannin et al. / Advanced Drug Delivery Reviews 73 (2014) 34–49[36] S. Smith, I. Sharkey, D. Campbell, Guidelines for rectal administration of anticon-
vulsant medication in children, Paediatr. Perinat. Drug Ther. 4 (2001) 140–147.
[37] V. Ivaturi, R. Kriel, R. Brundage, G. Loewen, H. Mansbach, J. Cloyd, Bioavailability of
intranasal vs. rectal diazepam, Epilepsy Res. 103 (2013) 254–261.
[38] S. Inthavilay, T. Franchard, Y. Meimei, E.A. Ashley, H. Barennes, Knowledge and ac-
ceptability of the rectal treatment route in Laos and its application for pre-referral
emergency malaria treatment, Malar. J. 9 (2010) 342.
[39] E. Chiappini, A. Parretti, P. Becherucci, M. Pierattelli, F. Bonsignori, L. Galli, M.M. de,
Parental and medical knowledge and management of fever in Italian pre-school
children, BMC Pediatr. 12 (2012) 97.
[40] D. Scolnik, E. Kozer, S. Jacobson, S. Diamond, N.L. Young, Comparison of oral versus
normal and high-dose rectal acetaminophen in the treatment of febrile children,
Pediatrics 110 (2002) 553–556.
[41] S.A. Lava, G.D. Simonetti, A. Ferrarini, G.P. Ramelli, M.G. Bianchetti, Regional differ-
ences in symptomatic fever management among paediatricians in Switzerland: the
results of a cross-sectional web-based survey, Br. J. Clin. Pharmacol. 75 (2013)
236–243.
[42] S.A. Karbasi, M. Modares-Mosadegh, M. Golestan, Comparison of antipyretic
effectiveness of equal doses of rectal and oral acetaminophen in children, J. Pediatr.
(Rio J.) 86 (2010) 228–232.
[43] F. Farahmand, K. Eftekhari, V. Modarresi, M. Najaﬁ-Sani, A. Khodadad, F. Motamed,
Comparing oral route parafﬁn oil versus rectal route for disimpaction in children
with chronic constipation; a randomized control trial, Iran. J. Pediatr. 20 (2010)
291–296.
[44] S.A. Lava, G.D. Simonetti, G.P. Ramelli, S. Tschumi, M.G. Bianchetti, Symptomatic
management of fever by Swiss board-certiﬁed pediatricians: results from a
cross-sectional, web-based survey, Clin. Ther. 34 (2012) 250–256.
[45] Rectal Preparations EP 01/2008:1145, European Pharmacopoeia, European Direc-
torate for the Quality of Medicines & HealthCare, Strasbourg, 2011. 732–733.
[46] DailyMed Current Medication Information [on line], Available on: http://dailymed.
nlm.nih.gov/dailymed (consulted 8-3-2013).
[47] U.S. Food and Drug Administration [on line], Available on: www.fda.gov/default.
htm (consulted 8-3-2013).
[48] Kusuri-no-shiori Drug Information Sheet [on line], Available on: http://www.rad-
ar.or.jp/siori/english/kensaku.cgi (consulted 8-3-2013).
[49] ANSM — Agence Nationale de sécurité du Médicament [on line], Available on:
http://ansm.sante.fr/ (consulted 8-3-2013).
[50] Thériaque [on line], Available on: http://www.theriaque.org (consulted 8-3-
2013).
[51] PharmNet.bund — the drug information portal of the Bund (Federal Government)
and the Laender (States) [on line], Available on: http://www.pharmnet-bund.de/
dynamic/de/index.html (consulted 8-3-2013).
[52] INFARMED— National Authority of Medicines and Health Products [on line], Avail-
able on: http://www.infarmed.pt/portal/page/portal/INFARMED (consulted 8-3-
2013).
[53] Agencia Española de Medicamentos y Productos Sanitarios [on line], Available on:
http://www.aemps.gob.es/ (consulted 8-3-2013).
[54] Home electronic Medicines Compendium [on line], Available on: http://www.
medicines.org.uk/emc/ (consulted 8-3-2013).
[55] M.F. Gomes, M.A. Faiz, J.O. Gyapong, M. Warsame, T. Agbenyega, A. Babiker, F.
Baiden, E.B. Yunus, F. Binka, C. Clerk, P. Folb, R. Hassan, M.A. Hossain, O. Kimbute,
A. Kitua, S. Krishna, C. Makasi, N. Mensah, Z. Mrango, P. Olliaro, R. Peto, T.J. Peto,
M.R. Rahman, I. Ribeiro, R. Samad, N.J. White, Pre-referral rectal artesunate to pre-
vent death and disability in severe malaria: a placebo-controlled trial, Lancet 373
(2009) 557–566.
[56] P. Dorosz, Guide pratique des médicaments, eleventh ed. Maloine, Paris, 1990.
[57] P. Dorosz, D. Vital Durand, C. Le Jeunne, Guide pratique des médicaments, thirty-
second ed. Maloine, Paris, 2012.
[58] N.C. Ahn, G.W. Andersen, A. Thomsen, N. Valentin, Preanaesthetic medication with
rectal diazepam in children, Acta Anaesthesiol. Scand. 25 (1981) 158–160.
[59] A. Bejersten, G.L. Olsson, L. Palmer, The inﬂuence of body weight on plasma con-
centration of atropine after rectal administration in children, Acta Anaesthesiol.
Scand. 29 (1985) 782–784.
[60] R.S. Hannallah, M.D. Abramowitz, W.A. McGill, B.S. Epstein, Rectal methohexitone
induction in pediatric outpatients: physostigmine does not enhance recovery,
Can. Anaesth. Soc. J. 32 (1985) 231–234.
[61] J.M. Julia, A. Rochette, C. Ricard, Y. Jullien, J. du Cailar, Comparative study of rectal
premedication with midazolam and ﬂunitrazepam in infants, Ann. Fr. Anesth.
Reanim. 3 (1984) 185–188.
[62] I.G. Kestin, W.B. McIlvaine, C.H. Lockhart, K.J. Kestin, M.A. Jones, Rectal
methohexital for induction of anesthesia in children with and without rectal aspi-
ration after sleep: a pharmacokinetic and pharmacodynamic study, Anesth. Analg.
67 (1988) 1102–1104.
[63] L.M.P. Liu, N.G. Goudsouzian, P.L. Liu, Rectal methohexital premedication in chil-
dren, a dose-comparison study, Anesthesiology 53 (1980) 343–345.
[64] L.M.P. Liu, P. Gaudreault, P.A. Friedman, N.G. Goudsouzian, Methohexital plasma
concentrations in children following rectal administration, Anesthesiology 62
(1985) 567–570.
[65] M.A.K. Mattila, M.K. Ruoppi, E. Ahlstrom-Bengs, H.M. Larni, P.O. Pekkola, Diazepam
in rectal solution as premedication in children, with special reference to serum
concentrations, Br. J. Anaesth. 53 (1981) 1269–1272.
[66] C. Saint-Maurice, C. Esteve, J. Holzer, Premedication with rectal midazolam. Effec-
tive dose in paediatric anaesthesia, Ann. Fr. Anesth. Reanim. 3 (1984) 181–184.
[67] T.J. White III, R.L. Siegle, G.J. Burckart, D.R. Ramey, Rectal thiopental for seda-
tion of children for computed tomography, J. Comput. Assist. Tomogr. 3
(1979) 286–288.[68] D. Westerling, Rectally administered morphine: plasma concentrations in children
premedicated with morphine in hydrogel and in solution, Acta Anaesthesiol.
Scand. 29 (1985) 653–656.
[69] J.O. Barrish, M.A. Gilger, Colon cleanout preparations in children and adolescents,
Gastroenterol. Nurs. 16 (1993) 106–109.
[70] L.M. Holle, B.E. Gidal, D.M. Collins, Valproate in status epilepticus, Ann.
Pharmacother. 29 (1995) 1042–1044.
[71] S. Miyazaki, C. Yokouchi, T. Nakamura, N. Hashiguchi, W.M. Hou, M. Takada,
Pluronic F-127 gels as a novel vehicle for rectal administration of indomethacin,
Chem. Pharm. Bull. (Tokyo) 34 (1986) 1801–1808.
[72] S. Miyazaki, F. Suisha, N. Kawasaki, M. Shirakawa, K. Yamatoya, D. Attwood,
Thermally reversible xyloglucan gels as vehicles for rectal drug delivery, J. Control.
Release 56 (1998) 75–83.
[73] Y. Yuan, Y. Cui, L. Zhang, H.P. Zhu, Y.S. Guo, B. Zhong, X. Hu, L. Zhang, X.H. Wang, L.
Chen, Thermosensitive and mucoadhesive in situ gel based on poloxamer as new
carrier for rectal administration of nimesulide, Int. J. Pharm. 430 (2012) 114–119.
[74] P.D. Walson, M. Halvorsen, J. Edge, M.J. Casavant, M.T. Kelley, Pharmacokinetic
comparison of acetaminophen elixir versus suppositories in vaccinated infants
(aged 3 to 36 months): a single-dose, open-label, randomized, parallel-group de-
sign, Clin. Ther. 35 (2013) 135–140.
[75] S. Ali, K. Maryam, Comparison of midazolamwith lidocaine and fentanyl for caudal
analgesia in children, J. Med. Sci. 7 (2007) 660–664.
[76] N. Bilenko, H. Tessler, R. Okbe, J. Press, R. Gorodischer, Determinants of antipyretic
misuse in children up to 5 years of age: a cross-sectional study, Clin. Ther. 28
(2006) 783–793.
[77] P.K. Birmingham, M.J. Tobin, T.K. Henthorn, D.M. Fisher, M.C. Berkelhamer, F.A.
Smith, K.B. Fanta, C.J. Coté, Twenty-four-hour pharmacokinetics of rectal acetamin-
ophen in children: an old drug with new recommendations, Anesthesiology 87
(1997) 244–252.
[78] M.C. Chang, Y.C. Chen, S.C. Chang, G.D. Smith, Knowledge of using acetaminophen
syrup and comprehension of written medication instruction among caregivers
with febrile children, J. Clin. Nurs. 21 (2012) 42–51.
[79] C.R.H. Cormack, S. Sudan, R. Addison, J. Keating, R.A. Sherwood, E.M.C. Ashley, The
pharmacokinetics of a single rectal dose of paracetamol (40 mg·kg−1) in children
with liver disease, Paediatr. Anaesth. 16 (2006) 417–423.
[80] M. Dahi-Taleghani, S. Mousavifard, S. Tahmoureszade, A. Dabbagh, Rectal acet-
aminophen versus peritonsillar inﬁltration of bupivacaine for postoperative anal-
gesia after adenotonsillectomy in children, Eur. Arch. Otorhinolaryngol. 268
(2011) 581–584.
[81] G.A. Dashti, S. Amini, E. Zanguee, The prophylactic effect of rectal acetaminophen
on postoperative pain and opioid requirements after adenotonsillectomy in chil-
dren, Middle East J. Anesthesiol. 20 (2009) 245–250.
[82] L.H. Goldstein,M. Berlin, M. Berkovitch, E. Kozer, Effectiveness of oral vs rectal acet-
aminophen: a meta-analysis, Arch. Pediatr. Adolesc. Med. 162 (2008) 1042–1046.
[83] E.S. Golladay, S. Hutter, E. Koehn, T. Hunt, R. Gutta, F. Gerbasi, C. Corpron, A. Hagan,
T. Dell, K. Selley, A comparison of caudal block and acetaminophen preemptive an-
algesia in pediatric peritoneoscopy, Pediatr. Endosurg. Innov. Tech. 7 (2003)
153–159.
[84] T.W. Hahn, S.W. Henneberg, R.J. Holm-Knudsen, K. Eriksen, S.N. Rasmussen, M.
Rasmussen, Pharmacokinetics of rectal paracetamol after repeated dosing in chil-
dren, Br. J. Anaesth. 85 (2000) 512–519.
[85] H.L. Helgadottir, M.E. Wilson, Parents' knowledge and choice of paracetamol dos-
ing forms in 3- to 6-year-old children, Scand. J. Caring Sci. 22 (2008) 93–97.
[86] V.M. Jones, Acetaminophen injection: a review of clinical information, J. Pain
Palliat. Care Pharmacother. 25 (2011) 340–349.
[87] A. Khalid, S.Z. Siddiqui, S. Haider, S. Aftab, Single dose caudal tramadol with
bupivacaine and bupivacaine alone in pediatric inguinoscrotal surgeries, J. Coll.
Phys. Surg. Pak. 17 (2007) 519–522.
[88] T.W. Kim, C.L. Rognerud, C.N. Ou, Accuracy in the alteration of acetaminophen sup-
positories, Anesth. Analg. 100 (2005) 1303–1305.
[89] H. Li, Y. Li, Y. Wang, J. Wang, C. Hou, Y. Lin, L. Wang, X. Yang, Evidence-based eval-
uation and selection of essential medicine for township health centre in China: 3.
common cold, Chin. J. Evid.-Based Med. 12 (2012) 868–877.
[90] C.J. Montgomery, J.P. McCormack, C.C. Reichert, C.P. Marsland, Plasma concentra-
tions after high-dose (45 mg·kg−1) rectal acetaminophen in children, Can. J.
Anaesth. 42 (1995) 982–986.
[91] S.A. Prins, M. Van Dijk, P. Van Leeuwen, S. Searle, B.J. Anderson, D. Tibboel, R.A.A.
Mathot, Pharmacokinetics and analgesic effects of intravenous propacetamol vs
rectal paracetamol in children after major craniofacial surgery, Paediatr. Anaesth.
18 (2008) 582–592.
[92] P. Sajedi, M. Nazem, K. Kaznavi, Effect of pre vs. post incision inguinal ﬁeld block on
postoperative pain after pediatric herniorrhaphy, a different approach, J. Res. Med.
Sci. 12 (2007) 1–6.
[93] B. Samaké, Y. Coulibaly, A. Diallo, M. Keita, M.A. Doumbia, Medical care of post-
operative pain in pediatric surgery: comparison of three protocols, Le Mali Méd.
24 (2009) 7–9.
[94] R. Singh, M. Kharbanda, N. Sood, V. Mahajan, C. Chatterji, Comparative evaluation
of incidence of emergence agitation and post-operative recovery proﬁle in paediat-
ric patients after isoﬂurane, sevoﬂurane and desﬂurane anaesthesia, Indian J.
Anaesth. 56 (2012) 156–161.
[95] J.D. Tobias, Weak analgesics and nonsteroidal anti-inﬂammatory agents in the
management of children with acute pain, Pediatr. Clin. N. Am. 47 (2000)
527–543.
[96] G. Weippl, N. Michos, E.J. Sundal, H. Stocker, Clinical experience and results of
treatment with suprofen in pediatrics. 2nd communication: use of suprofen sup-
positories as an antipyretic in children with fever due to acute infections/a
47V. Jannin et al. / Advanced Drug Delivery Reviews 73 (2014) 34–49single-blind controlled study of suprofen versus paracetamol, Drug Res. (Arzneim.
Forsch.), 35 (1985) 1724–1727.
[97] E.S. Adarsh, R. Mane, C.S. Sanikop, S.M. Sagar, Effect of pre-operative rectal
diclofenac suppository on post-operative analgesic requirement in cleft palate re-
pair: a randomised clinical trial, Indian J. Anaesth. 56 (2012) 265–269.
[98] F. Bano, S. Haider, S.T. Sultan, Comparison of caudal bupivacaine and bupivacaine-
midazolam for peri and postoperative analgesia in children, J. Coll. Phys. Surg. Pak.
14 (2004) 65–68.
[99] D.K. Bhowmick, K.M. Akhtaruzzaman, N. Ahmed, M.S. Islam, M.M. Hossain, M.M.
Islam, Postoperatve pain relief in children after subumbilical surgeries—a compar-
ison between caudal bupivacaine and bupivacaine-clonidine, Mymensingh Med. J.
20 (2011) 93–97.
[100] J. Borkar, N. Dave, Analgesic efﬁcacy of caudal block versus diclofenac suppository
and local anesthetic inﬁltration following pediatric laparoscopy, J. Laparoendosc.
Adv. Surg. Tech. A 15 (2005) 415–418.
[101] D. Findlow, L.M. Aldridge, E. Doyle, Comparison of caudal block using bupivacaine
and ketamine with ilioinguinal nerve block for orchidopexy in children, Anaesthe-
sia 52 (1997) 1110–1113.
[102] N. Gupta, R. Wakhloo, A. Mehta, D. Wali, S.D. Gupta, Post-operative analgesia in
children: caudal block with bupivacaine, rectal diclofenac and combination of
both, J. Anaesthesiol. Clin. Pharmacol. 24 (2008) 321–324.
[103] S. Gupta, R. Maheshwari, S.C. Dulara, Wound instillation with 0.25% bupivacaine as
continuous infusion following hysterectomy, Middle East J. Anesthesiol. 18 (2005)
595–610.
[104] I.H. Littlejohn, M.M. Tarling, P.J. Flynn, A.J. Ordman, A. Aiken, Post-operative pain
relief in children following extraction of carious deciduous teeth under general an-
aesthesia: a comparison of nalbuphine and diclofenac, Eur. J. Anaesthesiol. 13
(1996) 359–363.
[105] P.R. Mcgowan, H. May, Z. Molnar, M. Cunliffe, A comparison of three methods of
analgesia in children having day case circumcision, Paediatr. Anaesth. 8 (1998)
403–407.
[106] K. Mikawa, K. Nishina, N. Maekawa, M. Asano, H. Obara, Oral clonidine
premedication reduces vomiting in children after strabismus surgery, Can. J.
Anaesth. 42 (1995) 977–981.
[107] S. Oztekin, H. Hepaguslar, A.A. Kar, D. Ozzeybek, O. Artikaslan, Z. Elar, Preemptive
diclofenac reduces morphine use after remifentanil-based anaesthesia for tonsil-
lectomy, Paediatr. Anaesth. 12 (2002) 694–699.
[108] A. Saeed, A.R. Khan, V. Lee, A. Aslam, J. Brain, M.P.L. Williams, L. Brennan, R.
Campbell, M. Samuel, Pain management for unilateral orchidopexy in children:
an effective regimen, World J. Surg. 33 (2009) 603–606.
[109] J.F. Standing, D. Tibboel, R. Korpela, K.T. Olkkola, Diclofenac pharmacokinetic meta-
analysis and dose recommendations for surgical pain in children aged 1–12 years,
Paediatr. Anaesth. 21 (2011) 316–324.
[110] T. Strengell, M. Uhari, R. Tarkka, J. Uusimaa, R. Alen, P. Lautala, H. Rantala, Antipy-
retic agents for preventing recurrences of febrile seizures: randomized controlled
trial, Arch. Pediatr. Adolesc. Med. 163 (2009) 799–804.
[111] P. Sylaidis, T.J. O'Neill, Diclofenac analgesia following cleft palate surgery, Cleft
Palate Craniofac. J. 35 (1998) 544–545.
[112] C.D. Van Der Marel, B.J. Anderson, J. Romsing, E. Jacqz-Aigrain, D. Tibboel,
Diclofenac and metabolite pharmacokinetics in children, Paediatr. Anaesth. 14
(2004) 443–451.
[113] I. Yamamoto, H. Yukioka, M. Fujimori, Clinical study of postoperative sedation in
pediatric patients. Effects of inhalation anesthetics and postoperative analgesics,
Jpn. J. Anesthesiol. 43 (1994) 1191–1195.
[114] D. Hadas, I. Youngster, A. Cohen, E. Leibovitch, I. Shavit, I. Erez, Y. Uziel, M.
Berkovitch, Premarketing surveillance of ibuprofen suppositories in febrile chil-
dren, Clin. Pediatr. 50 (2011) 196–199.
[115] A. Boucher, P. Vilette, N. Crassard, N. Bernard, J. Descotes, Urinary toxicological
screening: analytical interference between niﬂumic acid and cannabis, Arch.
Pediatr. 16 (2009) 1457–1460.
[116] J.M. Cholette, L. Mamikonian, G.M. Alﬁeris, N. Blumberg, N.B. Lerner, Aspirin
resistance following pediatric cardiac surgery, Thromb. Res. 126 (2010)
200–206.
[117] J. Saugier, Migraine in children, Rev. Med. Tours 12 (1978) 41–45.
[118] H. Kokki, H. Tuomilehto, K. Tuovinen, Pain management after adenoidectomy with
ketoprofen: comparison of rectal and intravenous routes, Br. J. Anaesth. 85 (2000)
836–840.
[119] A. Messeri, P. Busoni, B. Noccioli, S. Murolo, G. Ivani, R. Grossetti, C. Gallini, L.
Maestri, G. Fedele, R. Novellini, Analgesic efﬁcacy and tolerability of ketoprofen
lysine salt vs paracetamol in common paediatric surgery. A randomized, single-
blind, parallel, multicentre trial, Paediatr. Anaesth. 13 (2003) 574–578.
[120] M. Shaban, S.M. Asida, Oral midazolam with low dose ketamine, fentanyl, or
ketoprofen for the prevention of emergence agitation after pediatric ambulatory
surgery, Egypt. J. Anaesth. 24 (2008) 27–33.
[121] H. Tuomilehto, H. Kokki, R. Ahonen, J. Nuutinen, Postoperative behavioral changes
in children after adenoidectomy, Arch. Otolaryngol. Head Neck Surg. 128 (2002)
1159–1164.
[122] R. Leaver, H. Wegner, S. Furman, A comparison of the antipyretic efﬁcacy of
mefenamic acid 126-mg suppository and 60-mg suspension in pediatric patients
and an evaluation of the local tolerability of the suppositories, Curr. Ther. Res.
Clin. Exp. 55 (1994) 645–652.
[123] C. Sims, C.M. Johnson, R. Bergesio, S.J. Delfos, E.A. Avraamides, Rectal indomethacin
for analgesia after appendicectomy in children, Anaesth. Intensive Care 22 (1994)
272–275.
[124] F. Cataldo, M.A. Trippiedi, G. Gueci, Clinical use of tinoridine in pediatrics, Curr.
Ther. Res. Clin. Exp. 33 (1983) 123–131.[125] S. Furukawa, T. Okada, Clinical effects of ampicillin suppository (KS-R1) on infec-
tions in pediatric ﬁeld, Jpn. J. Antibiot. 36 (1983) 1877–1881.
[126] K. Kida, N. Watanabe, H. Matsuda, M. Murase, Clinical effects of ampicillin suppos-
itory (KS-R1) in pediatric ﬁeld, Jpn. J. Antibiot. 36 (1983) 1882–1887.
[127] Y. Kobayashi, T. Haruta, S. Kuroki, K. Okura, Clinical evaluation of ampicillin sup-
pository (KS-R1), Jpn. J. Antibiot. 36 (1983) 1871–1876.
[128] T. Motohiro, T. Fujimoto, T. Nishiyama, Comparative well-controlled study of ampi-
cillin rectal suppository versus intravenous administration of ampicillin against
acute pneumonia in pediatric ﬁeld, Jpn. J. Antibiot. 36 (1983) 1785–1805.
[129] T. Motohiro, K. Tanaka, T. Koga, Fundamental study on ampicillin suppository (KS-
R1) in adults and children, Jpn. J. Antibiot. 36 (1983) 1713–1768.
[130] S. Nakazawa, H. Sato, K. Niino, Fundamental and clinical studies of ampicillin sup-
pository (KS-R1) in pediatric ﬁeld, Jpn. J. Antibiot. 36 (1983) 1814–1820.
[131] T. Nishimura, T. Takashima, K. Tabuki, Comparative well-controlled study of ampi-
cillin rectal suppository versus oral form of ampicillin against acute respiratory
tract infections in pediatric ﬁeld, Jpn. J. Antibiot. 36 (1983) 1769–1784.
[132] T. Nishimura, K. Tabuki, T. Takashima, Basic and clinical studies of ampicillin sup-
pository (KS-R1) in pediatric ﬁeld, Jpn. J. Antibiot. 36 (1983) 1863–1870.
[133] Z. Sakaguchi, E. Asano, Y. Miyauchi, K. Ohara, T. Okamoto, Clinical experience with
ampicillin suppository (KS-R1) in the pediatric ﬁeld, Jpn. J. Antibiot. 36 (1983)
1888–1894.
[134] T. Sekiguchi, T. Ichioka, T. Hosoda, M. Masuda, M. Miyao, Clinical experience with
ampicillin suppository (KS-R1) in bacterial infection of children, Jpn. J. Antibiot.
36 (1983) 1895–1899.
[135] T. Shinozaki, B. Kim, O. Arimasu, S. Hashira, R. Fujii, Clinical studies of ampicillin
suppository (KS-R1) in pediatric ﬁeld, Jpn. J. Antibiot. 36 (1983) 1821–1826.
[136] M. Yafuso, T. Nakashima, K. Aso, Clinical studies on ampicillin suppository (KS-R1)
in the ﬁeld of pediatric infection, Jpn. J. Antibiot. 36 (1983) 1846–1850.
[137] S. Furukawa, T. Okada, Clinical effects of ceftizoxime suppository on pediatric infec-
tion, Jpn. J. Antibiot. 38 (1985) 2943–2951.
[138] K. Kida, H. Matsuda, Clinical use of ceftizoxime suppositories in pediatric infection,
Jpn. J. Antibiot. 38 (1985) 2970–2976.
[139] K. Sunakawa, A. Hirota, N. Saito, Y. Ishizuka, Clinical studies of ceftizoxime suppos-
itory in pediatric ﬁeld, Jpn. J. Antibiot. 38 (1985) 2889–2895.
[140] T. Kauss, K. Gaudin, A. Gaubert, B. Ba, S. Tagliaferri, F. Fawaz, J.L. Fabre, J.M. Boiron,
X. Lafarge, N.J. White, P.L. Olliaro, P. Millet, Screening paediatric rectal forms of
azithromycin as an alternative to oral or injectable treatment, Int. J. Pharm. 436
(2012) 624–630.
[141] T. Kauss, A. Gaubert, C. Boyer, B.B. Ba, M. Manse, S. Massip, J.M. Léger, F. Fawaz, M.
Lembege, J.M. Boiron, X. Lafarge, N. Lindegardh, N.J. White, P. Olliaro, P. Millet, K.
Gaudin, Pharmaceutical development and optimization of azithromycin supposito-
ry for paediatric use, Int. J. Pharm. 441 (2013) 218–226.
[142] S. Campos, P. de la Cerda, A. Rivera, Fatal artesunate toxicity in a child, J. Pediatr.
Infect. Dis. 3 (2008) 69–75.
[143] K. Gaudin, T. Kauss, A. Gaubert, V. Viaud, J.P. Dubost, P. Olliaro, N.J. White, P. Millet,
Simultaneous determination of artemether and azithromycin in suppositories by
reversed phase HPLC, Anal. Lett. 44 (2011) 2732–2743.
[144] D.A. Van Riet-Nales, S.Wang, A. Saint-Raymond, J.L. Robert, The EMA quality guide-
line on the pharmaceutical development of medicines for paediatric use, Int. J.
Pharm. 435 (2012) 132–134.
[145] L.M. Chiang, H.S. Wang, H.H. Shen, S.T. Deng, C.H. Tseng, Y.I. Chen, M.L. Chou, P.C.
Hung, K.L. Lin, Rectal diazepam solution is as good as rectal administration of intra-
venous diazepam in the ﬁrst-aid cessation of seizures in children with intractable
epilepsy, Pediatr. Neonatol. 52 (2011) 30–33.
[146] Y. Hirabayashi, A. Okumura, T. Kondo, M. Magota, S. Kawabe, N. Kando, H.
Yamaguchi, J. Natsume, T. Negoro, K.Watanabe, Efﬁcacy of a diazepam suppository
at preventing febrile seizure recurrence during a single febrile illness, Brain and
Development 31 (2009) 414–418.
[147] T. Tanabe, Y. Awaya, T. Matsuishi, K. Iyoda, T. Nagai, M. Kurihara, K. Yamamoto, K.
Minagawa, K. Maekawa,Management of and prophylaxis against status epilepticus
in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome)—
a nationwide questionnaire survey in Japan, Brain and Development 30 (2008)
629–635.
[148] B. Buchan, G. Kay, K.H. Matthews, D. Cairns, Suppository formulations as a potential
treatment for nephropathic cystinosis, J. Pharm. Sci. 101 (2012) 3729–3738.
[149] Z. Kato, A. Yamagishi, M. Nakamura, N. Kondo, Theophylline-associated status ep-
ilepticus in an infant: pharmacokinetics and the risk of suppository use, World J.
Pediatr. 5 (2009) 316–318.
[150] N. Kolassa, Menthol differs from other terpenic essential oil constituents, Regul.
Toxicol. Pharmacol. 65 (2013) 115–118.
[151] N. Nishimura, N. Doi, T. Uemura, T. Taketani, G. Hayashi, T. Kasai, R. Kanai, S.
Yamaguchi, K. Iwamoto, K. Naora, Pharmaceutical analysis and clinical efﬁcacy of
Kampo medicine, maoto, extract suppository against pediatric febrile symptoms,
Yakugaku Zasshi 129 (2009) 759–766.
[152] H. Kasai, K. Sasaki, H. Tsujinaga, T. Hoshino, Pain management in advanced pediat-
ric cancer patients — a proposal of the two-step analgesic ladder, Japan. J.
Anesthesiol. 44 (1995) 885–889.
[153] W.E. Cayley, Antiemetics for acute gastroenteritis-related vomiting in children and
adolescents, Am. Fam. Physician 85 (2012) 1054–1056.
[154] Z. Fedorowicz, V.A. Jagannath, B. Carter, Antiemetics for reducing vomiting related
to acute gastroenteritis in children and adolescents, Sao Paulo Med. J. 130 (2012)
270.
[155] U. Uhlig, N. Pfeil, G. Gelbrich, C. Spranger, S. Syrbe, B. Huegle, B. Teichmann, T.
Kapellen, P. Houben, W. Kiess, H.H. Uhlig, Dimenhydrinate in children
with infectious gastroenteritis: a prospective, RCT, Pediatrics 124 (2009)
e622–e632.
48 V. Jannin et al. / Advanced Drug Delivery Reviews 73 (2014) 34–49[156] I.D. Welters, M. Graef, T. Menges, C. Beikirch, H. Kaufmann, G. Hempelmann, Post-
operative nausea and vomiting after Faden operation, Graefes Arch. Clin. Exp.
Ophthalmol. 238 (2000) 59–63.
[157] D.A. Christakis, J.A. Wright, F. Rivara, P. Saur, Promethazine therapy for gastroen-
teritis: towards a better understanding of use, risks and beneﬁts, Ambul. Child
Health 4 (1998) 181–187.
[158] F. Dhondt, S. Traen, M. van Eygen, Domperidone (R 33 812) suppositories: an effec-
tive antiemetic agent in diverse pediatric conditions. A multicenter trial, Curr. Ther.
Res. Clin. Exp. 24 (1978) 912–923.
[159] M. van Eygen, E. Heck, F. Dhondt, L. Ameryckx, H. Van Ravensteyn, A double-blind
comparison of domperidone and metoclopramide suppositories in the treatment
of nausea and vomiting in children, Postgrad. Med. J. 55 (1979) 36–39.
[160] A. Iwamoto, R. Uchiumi, T. Hidaka, K. Taniguchi, N. Honda, Y. Okuno, The efﬁcacy of
midazolam-famotidine suppository for premedication in children, Japan. J.
Anesthesiol. 44 (1995) 263–267.
[161] N. Kambara, S. Kitamura, A. Taniguchi,W. Hamao, M. Matsuyama, Premedication in
children: a comparison of oral midazolam and rectal bromazepam, Japan. J.
Anesthesiol. 44 (1995) 1707–1711.
[162] M. Shimoyama, T. Mizuguchi, S. Yorozu, Premedication in children. A clinical trial
of bromazepam and chloral hydrate suppositories, Japan. J. Anesthesiol. 39
(1990) 64–69.
[163] C. Koizumi, Y. Yamamoto, K. Tohyama, Y. Mizukoshi, Diazepam suppository for
premedication of anesthesia in children, Hokuriku J. Anesthesiol. 31 (1997) 19–22.
[164] Y. Sakurai, T. Obata, A. Odaka, K. Terui, M. Tamura, H. Miyao, Buccal administration
of dexmedetomidine as a preanesthetic in children, J. Anesth. 24 (2010) 49–53.
[165] R. Uchiumi, T. Hidaka, A. Miyagawa, K. Sugino, K. Taniguchi, N. Honda, Clinical eval-
uation of diazepam suppository for premedication in children, Japan. J. Anesthesiol.
43 (1994) 102–105.
[166] F. Marchat, B. Moulinier, R. De Prado, R. Lambert, L'oesophago-gastro-
duodenoscopie en pédiatrie, Acta Endos. 5 (1975) 15–19.
[167] A. McEwan, P.E. Sigston, K.A. Andrews, H.A. Hack, A.M.C. Jenkins, L. May, N.
Llewelyn, A. Mackersie, A comparison of rectal and intramuscular codeine phos-
phate in children following neurosurgery, Paediatr. Anaesth. 10 (2000) 189–193.
[168] V. Owczarzak, J. Haddad, Comparison of oral versus rectal administration of acet-
aminophen with codeine in postoperative pediatric adenotonsillectomy patients,
Laryngoscope 116 (2006) 1485–1488.
[169] G.K. Blair, J.J. Murphy, G.C. Fraser, Internal sphincterotomy in post-pull-through
Hirschsprung's disease, J. Pediatr. Surg. 31 (1996) 843–845.
[170] S.M. Borowitz, D.J. Cox, B. Kovatchev, L.M. Ritterband, J. Sheen, J. Sutphen, Treat-
ment of childhood constipation by primary care physicians: efﬁcacy and predictors
of outcome, Pediatrics 115 (2005) 873–877.
[171] M. Bulut, G. Tekant, Encopretic children: experience with ﬁfty cases, Turk. J.
Pediatr. 33 (1991) 167–172.
[172] R. Burgers, E. Bonanno, E. Madarena, F. Graziano, L. Pensabene, W. Gardner, H.
Mousa, M.A. Benninga, C. Di Lorenzo, The care of constipated children in prima-
ry care in different countries, Acta Paediatrica, Int. J. Paediatr. 101 (2012)
677–680.
[173] S.J. Grifﬁn, E.J. Parkinson, P.S.J. Malone, Bowel management for paediatric patients
with faecal incontinence, J. Pediatr. Urol. 4 (2008) 387–392.
[174] S.N. Khadr, S.E. Ibhanesebhor, C. Rennix, H.E. Fisher, C.M. Manjunatha, D. Young, R.
C. Abara, Randomized controlled trial: impact of glycerin suppositories on time to
full feeds in preterm infants, Neonatology 100 (2011) 169–176.
[175] A. Lachaux, P. Roy, Constipation in children, Arch. Pediatr. 15 (2008) 95–101.
[176] S.R. Leibold, Achieving continencewith a neurogenic bowel, Pediatr. Clin. N. Am. 57
(2010) 1013–1025.
[177] M.C. Luxem, E.R. Christophersen, P.C. Purvis, D.M. Baer, Behavioral-medical treat-
ment of pediatric toileting refusal, J. Dev. Behav. Pediatr. 18 (1997) 34–41.
[178] P. Masi, E. Miele, A. Staiano, Pediatric anorectal disorders, Gastroenterol. Clin. N.
Am. 37 (2008) 709–730.
[179] R. Seth, M.B. Heyman, Management of constipation and encopresis in infants and
children, Gastroenterol. Clin. N. Am. 23 (1994) 621–636.
[180] E.R. Wald, T.D. Jagodzinski, S.C.L. Moyer, A. Wald, J.C. Eickhoff, M.B. Edmonson,
Validation and clinical utility of a bowel habit questionnaire in school-age children,
J. Pediatr. Gastroenterol. Nutr. 53 (2011) 520–523.
[181] M.B. Heyman, J. Kierkus, J. Spénard, H. Shbaklo, M. Giguere, Efﬁcacy and safety of
mesalamine suppositories for treatment of ulcerative proctitis in children and ad-
olescents, Inﬂamm. Bowel Dis. 16 (2010) 1931–1939.
[182] E.R. Perito, E. Mileti, D.H. Dalal, S.J. Cho, L.D. Ferrell, M. McCracken, M.B. Heyman,
Solitary rectal ulcer syndrome in children and adolescents, J. Pediatr. Gastroenterol.
Nutr. 54 (2012) 266–270.
[183] C.Y. Wu, L.Z. Benet, Predicting drug disposition via application of BCS: transport/
absorption/elimination interplay and development of a biopharmaceutics drug
disposition classiﬁcation system, Pharm. Res. 22 (2005) 11–23.
[184] R.C. Moreton, Suppository bases, hard fat, in: R.C. Rowe, P.J. Sheskey, W.G.
Cook, M.E. Fenton (Eds.), Handbook of Pharmaceutical Excipients, Pharmaceu-
tical Press, London — Philadelphia, 2012, pp. 831–835.
[185] C. De Muynck, C. Cuvelier, D. Van Steenkiste, L. Bonnarens, J.P. Remon, Rectal mu-
cosa damage in rabbits after subchronical application of suppository bases, Pharm.
Res. 8 (1991) 945–950.
[186] H.G. Kristensen, WHO guideline development of paediatric medicines: points to
consider in pharmaceutical development, Int. J. Pharm. 435 (2012) 134–135.
[187] B. Barner, D. Wallick, Polyethylene glycol, in: R.C. Rowe, P.J. Sheskey, W.G.
Cook, M.E. Fenton (Eds.), Handbook of Pharmaceutical Excipients, Pharmaceu-
tical Press, London — Philadelphia, 2012, pp. 585–591.
[188] A.A. Fisher, Immediate and delayed allergic contact reactions to polyethylene
glycol, Contact Dermatitis 4 (1978) 135–138.[189] V. Fabiano, C. Mameli, G.V. Zuccotti, Paediatric pharmacology: remember the ex-
cipients, Pharmacol. Res. 63 (2011) 362–365.
[190] Disintegration of Suppositories and Pessaries EP 01/2008:20902, European Phar-
macopoeia, European Directorate for the Quality of Medicines & HealthCare, Stras-
bourg, 2008. 265–266.
[191] Softening Time Determination of Lipophilic Suppositories EP 01/2008:20922,
European Pharmacopoeia, European Directorate for the Quality of Medicines &
HealthCare, Strasbourg, 2011. 288.
[192] Dissolution Test for Lipophilic Solid Dosage Forms EP 01/2008:20942, European
Pharmacopoeia, European Directorate for the Quality of Medicines & HealthCare,
Strasbourg, 2011. 319–320.
[193] Uniformity ofMass of Single-Dose Preparations EP 01/2008:20905, European Phar-
macopoeia, European Directorate for the Quality of Medicines & HealthCare, Stras-
bourg, 2011. 265–266.
[194] Uniformity of Content of Single-Dose Preparations EP 01/2008:20906, European
Pharmacopoeia, European Pharmacopoeia, European Directorate for the Quality
of Medicines & HealthCare, Strasbourg, 2011. 266.
[195] R. Sagraves, Pediatric dosing and dosage forms, in: J. Swarbrick, J.C. Boylan (Eds.),
Encyclopedia of Pharmaceutical Technology, Marcel Dekker, Inc., New York,
2002, pp. 2045–2066.
[196] R. Gandhi, R. Sunder, Postoperative analgesic efﬁcacy of single high dose and low
dose rectal acetaminophen in pediatric ophthalmic surgery, J. Anaesthesiol. Clin.
Pharmacol. 28 (2012) 460–464.
[197] S.M. Heidari, S.Z. Mirlohi, S.J. Hashemi, Comparison of the preventive analgesic ef-
fect of rectal ketamine and rectal acetaminophen after pediatric tonsillectomy, Int.
J. Prev. Med. 3 (2012) S150–S155.
[198] E.M. Tinner, I. Hoesli, K. Jost, N. Schobi, M.Y. Ulrich, T. Burkhardt, A. Krafft, H.U.
Bucher, D. Surbek, M. Nelle, C. Buhrer, Rectal paracetamol in newborn infants
after assisted vaginal delivery may increase pain response, J. Pediatr. 162 (2013)
62–66.
[199] J.D. Losek, Acetaminophen dose accuracy and pediatric emergency care, Pediatr.
Emerg. Care 20 (2004) 285–288.
[200] S.M. Mireskandari, J. Makarem, Effect of rectal diclofenac and acetaminophen alone
and in combination on postoperative pain after cleft palate repair in children, J.
Craniofac. Surg. 22 (2011) 1955–1959.
[201] H. Kokki, M. Karvinen, P. Suhonen, Pharmacokinetics of intravenous and rectal
ketoprofen in young children, Clin. Pharmacokinet. 42 (2003) 373–379.
[202] B. Uldum, A.L. Hallonsten, S. Poulsen, Midazolam conscious sedation in a large
Danish municipal dental service for children and adolescents, Int. J. Paediatr.
Dent. 18 (2008) 256–261.
[203] A.G. Rowland, A.M. Gill, A.B. Stewart, R.E. Appleton, K.A. Al, C. Cramp, L.K. Yeung,
Review of the efﬁcacy of rectal paraldehyde in the management of acute and
prolonged tonic–clonic convulsions, Arch. Dis. Child. 94 (2009) 720–723.
[204] World Malaria Report, WHO press, Geneva, 2013.
[205] E. Landais, C. Poisson, J.L. Condamine, Analysis of 1697 cases of childhood malaria
treated using intra-rectal Quinimax (QIR) in the Tilaberi health district in Niger,
Med. Trop. (Mars.) 67 (2007) 471–476.
[206] J.L. Ndiaye, R.C. Tine, B. Faye, H.L. Dieye el, P.A. Diack, V. Lameyre, O. Gaye, H.D. Sow,
Pilot feasibility study of an emergency paediatric kit for intra-rectal quinine admin-
istration used by the personnel of community-based health care units in Senegal,
Malar. J. 6 (2007) 152.
[207] K. Pengsaa, C. Sirivichayakul, K. Na-Bangchang, I. Thaiarporn, A. Chaivisuth, A.
Wongsuwan, P. Attanath, C. Pojjaroen-Anant, P. Wisetsing, P. Chanthavanich, A.
Sabchareon, Life-saving rectal artesunate for complicated malaria in children,
Southeast Asian, J. Trop. Med. Public Health 36 (2005) 597–601.
[208] H.A. Karunajeewa, K.F. Ilett, K. Dufall, A. Kemiki, M. Bockarie, M.P. Alpers, P.H.
Barrett, P. Vicini, T.M. Davis, Disposition of artesunate and dihydroartemisinin
after administration of artesunate suppositories in children from Papua New
Guinea with uncomplicated malaria, Antimicrob. Agents Chemother. 48 (2004)
2966–2972.
[209] S. Krishna, T. Planche, T. Agbenyega, C. Woodrow, D. Agranoff, G. Bedu-Addo, A.
K. Owusu-Ofori, J.A. Appiah, S. Ramanathan, S.M. Mansor, V. Navaratnam,
Bioavailability and preliminary clinical efﬁcacy of intrarectal artesunate in
Ghanaian children with moderate malaria, Antimicrob. Agents Chemother. 45
(2001) 509–516.
[210] R.C. Tine, B. Faye, C.T. Ndour, J.L. Ndiaye, M. Ndiaye, C. Bassene, P. Magnussen, I.C.
Bygbjerg, K. Sylla, J.D. Ndour, O. Gaye, Impact of combining intermittent preventive
treatment with home management of malaria in children less than 10 years in a
rural area of Senegal: a cluster randomized trial, Malar. J. 10 (2011) 358.
[211] E.A. Gomez, M.H. Jurado, N. Cambon, Randomised efﬁcacy and safety study of two
3-day artesunate rectal capsule/meﬂoquine regimens versus artesunate alone for
uncomplicated malaria in Ecuadorian children, Acta Trop. 89 (2003) 47–53.
[212] C. Sirivichayakul, A. Sabchareon, K. Pengsaa, I. Thaiarporn, A. Chaivisuth, K. Na-
Bangchang, P. Wisetsing, P. Chanthavanich, C. Pojjaroen-Anant, Comparative
study of the effectiveness and pharmacokinetics of two rectal artesunate/oral mef-
loquine combination regimens for the treatment of uncomplicated childhood
falciparum malaria, Ann. Trop. Paediatr. 27 (2007) 17–24.
[213] P. Wilairatna, S. Krudsood, U. Silachamroon, P. Singhasivanon, S. Vannaphan, S.
Faithong, M. Klabprasit, S.N. Bangchang, P. Olliaro, S. Looareesuwan, Clinical trial
of sequential treatments of moderately severe and severe malaria with
dihydroartemisinin suppository followed by meﬂoquine in Thailand, Am. J. Trop.
Med. Hyg. 63 (2000) 290–294.
[214] B.R. Ogutu, C.R. Newton, J. Crawley, S.N. Muchohi, G.O. Otieno, G. Edwards, K.
Marsh, G.O. Kokwaro, Pharmacokinetics and anticonvulsant effects of diazepam
in children with severe falciparum malaria and convulsions, Br. J. Clin. Pharmacol.
53 (2002) 49–57.
49V. Jannin et al. / Advanced Drug Delivery Reviews 73 (2014) 34–49[215] J. Achan, J. Byarugaba, H. Barennes, J.K. Tumwine, Rectal versus intravenous
quinine for the treatment of childhood cerebral malaria in Kampala, Uganda: a
randomized, double-blind clinical trial, Clin. Infect. Dis. 45 (2007) 1446–1452.
[216] H. Barennes, T. Balima-Koussoube, N. Nagot, J.C. Charpentier, E. Pussard, Safety and
efﬁcacy of rectal compared with intramuscular quinine for the early treatment of
moderately severe malaria in children: randomised clinical trial, BMJ 332 (2006)
1055–1059.
[217] E. Pussard, C. Straczek, I. Kabore, A. Bicaba, T. Balima-Koussoube, P. Bouree, H.
Barennes, Dose-dependent resorption of quinine after intrarectal administration
to children with moderate Plasmodium falciparum malaria, Antimicrob. Agents
Chemother. 48 (2004) 4422–4426.
[218] J.R. Aceng, J.S. Byarugaba, J.K. Tumwine, Rectal artemether versus intravenous qui-
nine for the treatment of cerebral malaria in children in Uganda: randomised clin-
ical trial, BMJ 330 (2005) 334.
[219] K.I. Barnes, J. Mwenechanya, M. Tembo, H. McIlleron, P.I. Folb, I. Ribeiro, F. Little, M.
Gomes, M.E. Molyneux, Efﬁcacy of rectal artesunate comparedwith parenteral qui-
nine in initial treatment of moderately severe malaria in African children and
adults: a randomised study, Lancet 363 (2004) 1598–1605.
[220] F. Esamai, P. Ayuo, W. Owino-Ongor, J. Rotich, A. Ngindu, A. Obala, F. Ogaro, L.
Quoqiao, G. Xingbo, L. Guangqian, Rectal dihydroartemisinin versus intravenous
quinine in the treatment of severe malaria: a randomised clinical trial, East Afr.
Med. J. 77 (2000) 273–278.
[221] L. Conteh, S. Yeung, Assessing the cost-effectiveness of prereferral rectal artesunate
for treatment of severe childhood malaria, Expert Rev. Pharmacoecon. Outcome
Res. 11 (2011) 141–145.
[222] Y. Tozan, E.Y. Klein, S. Darley, R. Panicker, R. Laxminarayan, J.G. Breman, Prereferral
rectal artesunate for treatment of severe childhood malaria: a cost-effectiveness
analysis, Lancet 376 (2010) 1910–1915.
[223] J. Buchanan, B. Mihaylova, A. Gray, N. White, Cost-effectiveness of pre-referral an-
timalarial, antibacterial, and combined rectal formulations for severe febrile illness,
PLoS ONE 5 (2010) e14446.
[224] E. Bergogne-Berezin, A. Bryskier, The suppository form of antibiotic administra-
tion: pharmacokinetics and clinical application, J. Antimicrob. Chemother. 43
(1999) 177–185.
[225] N.S. Barakat, In vitro and in vivo characteristics of a thermogelling rectal delivery
system of etodolac, AAPS Pharm. Sci. Tech. 10 (2009) 724–731.
[226] K. Gaudin, A. Barbaud, C. Boyer, M.H. Langlois, A.M. Lagueny, J.P. Dubost, P. Millet, F.
Fawaz, In vitro release and stability of an artesunate rectal gel suitable for pediatric
use, Int. J. Pharm. 353 (2008) 1–7.
[227] A.A. Kofﬁ, F. Agnely, G. Ponchel, J.L. Grossiord, Modulation of the rheological and
mucoadhesive properties of thermosensitive poloxamer-based hydrogels intended
for the rectal administration of quinine, Eur. J. Pharm. Sci. 27 (2006) 328–335.
[228] A.A. Kofﬁ, F. Agnely, M. Besnard, B.J. Kablan, J.L. Grossiord, G. Ponchel, In vitro and
in vivo characteristics of a thermogelling and bioadhesive delivery system
intended for rectal administration of quinine in children, Eur. J. Pharm. Biopharm.
69 (2008) 167–175.
[229] C.S. Yong, H. Sah, Y. Jahng, H.W. Chang, J.K. Son, S.H. Lee, T.C. Jeong, J.D. Rhee, S.H.
Baek, C.K. Kim, H.G. Choi, Physicochemical characterization of diclofenac sodium-
loaded poloxamer gel as a rectal delivery system with fast absorption, Drug Dev.
Ind. Pharm. 29 (2003) 545–553.
[230] R. Yahagi, Y. Machida, H. Onishi, Mucoadhesive suppositories of ramosetron hydro-
chloride utilizing Carbopol, Int. J. Pharm. 193 (2000) 205–212.
[231] A. El-Kamel, M. El-Khatib, Thermally reversible in situ gelling carbamazepine liquid
suppository, Drug Deliv. 13 (2006) 143–148.
[232] A.A. Ramadan, Preparation, characterization and in-vivo evaluation of double-
phased mucoadhesive suppositories containing diclofenac in rats, J. Appl. Sci.
Res. 8 (2012) 746–752.
[233] R. Yahagi, H. Onishi, Y. Machida, Preparation and evaluation of double-phased
mucoadhesive suppositories of lidocaine utilizing Carbopol and white beeswax, J.
Control. Release 61 (1999) 1–8.
[234] J. Hanaee, Y. Javadzadeh, S. Taftachi, D. Farid, A. Nokhodchi, The role of various sur-
factants on the release of salbutamol from suppositories, Farmaco 59 (2004)
903–906.
[235] E.R. Cooper, Increased skin permeability for lipophilic molecules, J. Pharm. Sci. 73
(1984) 1153–1156.
[236] M.U. Adikwu, Evaluation of snail mucin motifs as rectal absorption enhancer for in-
sulin in non-diabetic rat models, Biol. Pharm. Bull. 28 (2005) 1801–1804.
[237] H. Shiohira,M. Fujii, N. Koizumi,M. Kondoh, Y.Watanabe, Novel chronotherapeutic
rectal aminophylline delivery system for therapy of asthma, Int. J. Pharm. 379
(2009) 119–124.[238] Y. Matsumoto, I. Yamamoto, Y. Watanabe, M. Matsumoto, Enhancing effect of vis-
cous sodium hyaluronate solution on the rectal absorption of morphine, Biol.
Pharm. Bull. 18 (1995) 1744–1749.
[239] T. Kondo, T. Irie, K. Uekama, Combination effects of alpha-cyclodextrin and
xanthan gum on rectal absorption and metabolism of morphine from hollow-
type suppositories in rabbits, Biol. Pharm. Bull. 19 (1996) 280–286.
[240] Y. Matsumoto, Y. Watanabe, T. Tojima, R. Murakoshi, C. Murakami, M. Matsumoto,
Rectal absorption enhancement of gentamicin in rabbits from hollow type suppos-
itories by sodium salicylate or sodium caprylate, Drug Des. Deliv. 4 (1989)
247–256.
[241] Y. Matsumoto, Y. Watanabe, I. Yamamoto, M. Matsumoto, Difference in rectal ab-
sorption of morphine from hollow-type and conventional suppositories in rabbits,
Biol. Pharm. Bull. 16 (1993) 150–153.
[242] D. Gugulothu, S. Pathak, S. Suryavanshi, S. Sharma, V. Patravale, Self-microemulsiﬁyng
suppository formulation of beta-artemether, AAPS Pharm. Sci. Tech. 11 (2010)
1179–1184.
[243] J.Y. Kim, Y.S. Ku, Enhanced absorption of indomethacin after oral or rectal admin-
istration of a self-emulsifying system containing indomethacin to rats, Int. J. Pharm.
194 (2000) 81–89.
[244] K. Welch, R. Ek, M. Stromme, Comparative drug release measurements in limited
amounts of liquid: a suppository formulation study, Curr. Drug Deliv. 3 (2006)
299–306.
[245] E.S. El-Leithy, D.S. Shaker, M.K. Ghorab, R.S. Abdel-Rashid, Evaluation of
mucoadhesive hydrogels loaded with diclofenac sodium-chitosan microspheres
for rectal administration, AAPS Pharm. Sci. Tech. 11 (2010) 1695–1702.
[246] K.C. Ofokansi, M.U. Adikwu, V.C. Okore, Preparation and evaluation of mucin-
gelatin mucoadhesive microspheres for rectal delivery of ceftriaxone sodium,
Drug Dev. Ind. Pharm. 33 (2007) 691–700.
[247] S.B. Patil, K.K. Sawant, Mucoadhesivemicrospheres: a promising tool in drug deliv-
ery, Curr. Drug Deliv. 5 (2008) 312–318.
[248] M. Gajewska, M. Sznitowska, S. Janicki, Diazepam submicron emulsions containing
soya-bean oil and intended for oral or rectal delivery, Pharmazie 56 (2001)
220–222.
[249] M. Sznitowska, S. Janicki, M. Gajewska, M. Kulik, Investigation of diazepam
lipospheres based on Witepsol and lecithin intended for oral or rectal delivery,
Acta Pol. Pharm. 57 (2000) 61–64.
[250] M. Sznitowska, M. Gajewska, S. Janicki, A. Radwanska, G. Lukowski, Bioavailability
of diazepam from aqueous-organic solution, submicron emulsion and solid lipid
nanoparticles after rectal administration in rabbits, Eur. J. Pharm. Biopharm. 52
(2001) 159–163.
[251] M.R. Neutra, P.A. Kozlowski, Mucosal vaccines: the promise and the challenge, Nat.
Rev. Immunol. 6 (2006) 148–158.
[252] J. Holmgren, C. Czerkinsky, Mucosal immunity and vaccines, Nat. Med. 11 (2005)
S45–S53.
[253] N. Parez, C. Fourgeux, A. Mohamed, C. Dubuquoy, M. Pillot, A. Dehee, A.
Charpilienne, D. Poncet, I. Schwartz-Cornil, A. Garbarg-Chenon, Rectal immuniza-
tion with rotavirus virus-like particles induces systemic and mucosal humoral im-
mune responses and protects mice against rotavirus infection, J. Virol. 80 (2006)
1752–1761.
[254] M. Yu, M. Vajdy, Mucosal HIV transmission and vaccination strategies through oral
compared with vaginal and rectal routes, Expert. Opin. Biol. Ther. 10 (2010)
1181–1195.
[255] M. Abolhassani, M. Lagranderie, P. Chavarot, A.M. Balazuc, G. Marchal, Mycobacte-
rium bovis BCG induces similar immune responses and protection by rectal and
parenteral immunization routes, Infect. Immun. 68 (2000) 5657–5662.
[256] S. Tengvall, D. O'Hagan, A.M. Harandi, Rectal immunization generates protective
immunity in the female genital tract against herpes simplex virus type 2 infection:
relative importance of myeloid differentiation factor 88, Antivir. Res. 78 (2008)
202–214.
[257] I.F. Barinskii, F.R. Makhmudov, Inactivated herpes simplex virus types 1 and 2
divaccine as an agent for effective immunoprophylaxis of recurrent genital herpes,
Vopr. Virusol. 55 (2010) 35–40.
[258] K. Hamajima, Y. Hoshino, K.Q. Xin, F. Hayashi, K. Tadokoro, K. Okuda, Systemic and
mucosal immune responses in mice after rectal and vaginal immunization with
HIV-DNA vaccine, Clin. Immunol. 102 (2002) 12–18.
[259] N. Dereuddre-Bosquet, L. Morellato-Castillo, J. Brouwers, P. Augustijns, K.
Bouchemal, G. Ponchel, O.H. Ramos, C. Herrera, M. Stefanidou, R. Shattock, L.
Heyndrickx, G. Vanham, P. Kessler, G.R. Le, L. Martin, MiniCD4 microbicide pre-
vents HIV infection of human mucosal explants and vaginal transmission of
SHIV(162P3) in cynomolgus macaques, PLoS Pathog. 8 (2012) e1003071.
